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 ABSTRACT  
 
REST is a zinc-finger transcription factor implicated in several processes such as 
maintenance of embryonic stem cell pluripotency and regulation of mitotic fidelity in 
non-neuronal cells [Chong et al., 1995]. The gene encodes for a 116-kDa protein that acts 
as a molecular platform for co-repressors recruitment and promotes modifications of 
DNA and histones [Ballas, 2005]. REST showed different apparent molecular weights, 
consistent with the possible presence of post-translational modifications [Lee et al., 2000]. 
Among these the most common is glycosylation, the covalent attachment of  
carbohydrates during or after protein synthesis [Apweiler et al., 1999]  
My thesis has ascertained, for the first time, the presence of glycan chians in the 
transcription factor REST. Through enzymatic deglycosylation and MS, oligosaccharide 
composition of glycan chains was evaluated: a complex mixture of glycans, composed of 
N-acetylgalactosamine, galactose and mannose, was observed thus confirming the 
presence of O- and N-linked glycan chains. Glycosylation site mapping was done using a 
18O-labeling method and MS/MS and twelve potential N-glycosylation sites were 
identified. The most probable glycosylation target residues were mutated through site-
directed mutagenesis and REST mutants were expressed in different cell lines. Variations 
in the protein molecular weight and mutant REST ability to bind the RE-1 sequence were 
analyzed. Gene reporter assays showed that, altogether, removal of N-linked glycan 
chains causes loss of transcriptional repressor function, except for mutant N59 which 
showed a slight residual repressor activity in presence of IGF-I.  
Taken togheter these results demonstrate the presence of complex glycan chians in the 
transcription factor REST: I have depicted their composition, started defining their 
position on the protein backbone and identified their possible role in the transcription 
factor functioning. Considering the crucial role of glycosylation and transcription factors 
activity in the aetiology of many diseases, any further knowledge could find important and 
interesting pharmacological application. 
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INTRODUCTION 
 
 
1. THE TRANSCRIPTION FACTOR REST 
 
Despite a genetic homogeneity, cells in multicellular organisms are structurally and 
functionally heterogeneous. The diversity of cell phenotype exists due to differential 
transcription programs precisely regulated by specific nuclear factors and induced upon 
differentiation: in fact the fate of a cell is ultimately determined by the way its genetic 
material and its protein scaffold are modified. 
The differences in gene expression programs arise during development and become 
heritable during cell proliferation: it becomes of crucial interest understanding the 
molecular mechanisms by which central nervous system-specific genes are expressed in 
the nervous system and repressed in other tissues.  
During neurogenesis, progenitor cells must select between neuronal versus non-neuronal 
fates; in the former case they must also select among a large repertoire of neuronal 
subtypes fates: these developmental decisions require the action of transcriptional 
regulatory proteins. Gene expression can be controlled by positively acting cell-type-
specific or tissue-specific transcription factors; however also negative-acting DNA 
regulatory elements can participate in preventing the expression of neuronal genes in non-
neuronal cell types or in inappropriate neuronal subtypes: these elements can be 
recognized by silencers, transcription factors that behave similar as enhancers but which 
have an opposite effect on transcription [Schoenherr and Anderson, 1995].  
Cells in the nervous system acquire distinct fates in response to extrinsic signals that 
activate repertoires of transcription factors in a region- and cell-type-specific manner, 
endowing each type of neuron with unique characteristics and determining the generation. 
Transcription factors play pivotal roles in regulating the generation of neural precursors, 
the regionalization of the nervous system and subsequent differentiation of specific cell 
types within this region. 
The loss of function or misexpression of a single transcription factor can be sufficient to 
alter neuron morphology, synaptic input, projection pattern or neurotransmitter 
phenotype [Bang and Goulding, 1996].  
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In 1995 two groups independently identified a gene encoding a zinc-finger protein that 
was suggested to function as a master regulator of the neuronal phenotype. The 
transcription factor REST, an RE-1-silencing transcription factor [Chong et al., 1995] also 
known as neuron-restrictive silencing factor NRSF [Schoenherr and Andreson 1995], 
blocks transcription of its target genes by binding to a specific consensus sequence that is 
present in the target genes’ regulatory region.  
The original proposed role for REST was that of a factor responsible for restricting 
neuronal gene expression to the nervous system, by silencing expression of these genes in 
non-neuronal cells: since its discovery as a negative regulator of neuronal differentiation, 
REST has been implicated in several processes such as maintenance of embryonic stem 
cell pluripotency, self-renewal and regulation of mitotic fidelity in non-neuronal cells.  
By fluorescence in situ hybridization REST gene (3365 base pairs) was assigned to the 
chromosomic region 4q12 [GeneBank NM_005612] [Cowan et al., 1996]. The gene 
encodes for a protein constituted by 1097 aminoacids: it is a 116-kDa Krüppel family zinc 
finger protein that contains a DNA-binding domain, composed of eight zinc-fingers, and 
one zinc finger at the carboxy terminal. The zinc finger domain, which includes 2 
conserved cysteine and 2 conserved histidine residues, have the ability to bind to both 
RNA and DNA. The DNA-binding domain of REST binds to a 21-bp consensus DNA 
sequence, the RE-1 binding site/neuron-restrictive silencer element (RE-1/NRSE), 
present in the target gene’s regulatory regions. In addition to the DNA binding domain 
(DBD), REST is composed of an N-terminal repressor domain and a C-terminal 
repressor domain, which contains a single zinc finger motif [Ballas and Mandel, 2005]: 
deletion to aminoacidic residues 76 or 44 totally abolished repression, suggesting that a 
repressor domain is located between residues 44 and 83. Aminoacid residues 1061-1097 
containing the C-terminally located zinc finger are also essential for the repression activity 
of REST, defining aminoacids 989-1097 as a second repression domain (Figure 1.1). 
REST protein is present at its highest level in the nuclei of pluripotent embryonic stem 
(ES) cells; as ES cells differentiate to neural progenitors REST mRNA levels stay 
relatively constant but REST protein is downregulated post-translationally to minimal 
levels. The release of REST from neuronal gene chromatin as progenitor differentiate into 
neurons is concomitant with its own transcriptional repression.  
By acting as an evolving molecular platform to which diverse factors may be recruited, 
REST promotes dynamic modifications of DNA, histones, nucleosomes and higher-order 
chromatin codes and helps maintaining genomic stability. 
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Figure 1.1: Schematic representation of REST protein domains. 
 
REST is obligatory for the correct development of vertebrates, since perturbations of its 
expression or function in the developing embryo results in the ectopic expression of 
neuronal genes in non-neuronal tissues and early embryonic lethality: mice homozygous 
null for REST showed brain malformation at embryonic day E9.5, followed by extensive 
apoptosis and lethality by E11.5. These results suggested an important role for REST in 
brain development where it acts as a molecular restraint for precocious neuronal 
differentiation [Chen et al., 1998]. 
Although the molecular weight calculated on REST sequence is about 116 kDa, using  
western blot this transcription factor appears to have distinct apparent molecular weights 
(Table 1.1): this difference could be explained by post-translational modifications of the 
proteins.  
In addition, several splice variants of REST were discovered encoding proteins with five 
or four zinc finger motifs [Palm et al., 1998]: two variants, termed REST4 and REST5, 
were only detected in neuronal tissues and are conserved in human, mouse and rat [Palm 
et al., 1999]. These transcripts are generated by alternative splicing of a neuron-specific 
exon (exon N) located between exons V and VI. REST4 in particular have an insertion of 
16 nucleotides followed by an inframe stop codon, so it retains the N-terminal repression 
domain and five of the eight zinc fingers. The biological function of REST4 is 
controversial: although it does not bind to the RE-1 itself, it acts as a dominant negative 
by inhibiting the binding of REST to the RE-1 sequence and regulating the repressor 
activity of REST [Shimojo et al., 1999].  
Both REST and REST4 interact with RILP, a LIM domain protein, necessary for nuclear 
traslocation, suggesting that REST action could also depend on its cellular environment 
[Shimojo and Hersh 2003]. REST protein was found to migrate on SDS-PAGE as a 
protein of ~200 kDa, while the predicted molecular weight, based on aminoacid sequence, 
is 116 kDa; the isoforms REST4  and REST5 migrated on SDS-PAGE as 53 kDa and 50 
kDa proteins, respectively, while the predicted molecular weights are 37 kDa and 33 kDa, 
consistent with glycosylation of the protein backbone. REST4, and presumably REST, 
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was found to be O-glycosylated between residues 87 and 152: however full length REST 
could contain additional glycosylation sites [Lee et al., 2000]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1: REST molecular weight in different cell lines. 
 
Additional layers of flexibility and specificity are conferred on the activity of the REST 
complex through several parameters that include its affinity for binding to different RE-1 
sites, the modulation via non-coding RNAs, and emerging post-transcriptional events. 
 
 
1.1 REST BINDING SITE 
 
REST binds to a 21 base-pair sequence termed RE-1 (Repressor Element-1)/NRSE 
(Neuron Restrictive Silencer Element) and found in the regulatory regions of its target 
genes. Several approaches, from bioinformatics to genome-wide binding experiments and 
study of diseases, have been used to define the RE-1 element and to identify REST target 
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genes: these strategies allowed the identification of 1892 putative RE-1s in the human 
genome.  
Starting from the Repressor Element-1 originally found in the 5’ flanking region of the 
voltage-gated sodium type II channel and superior cervical ganglion 10 genes, a 21-bp element has 
been identified in the regulatory regions of many neuron-specific genes. These genes 
include those encoding ion channels (e.g., NaV1.3, Kv3.4, and Cavl.3), neurotransmitter-
synthesizing enzymes and receptors (e.g., M4 muscarinic, D3 dopamine, and γ-
aminobutyric acid type β3 receptors), transporters (e.g., γ-aminobutyric acid transporter 4), 
neurotrophic receptors and proteins involved in vesicular trafficking (e.g., synaptosomal-
associated protein SNAP25; synaptotagmins IV, V and VII; syntaxin 8; Rab3), neuronal 
cytoskeleton (tubulin β3) and axonal guidance (e.g., SCG10, stathmin 3, netrin-2, 
roundabout, semaphorin 5A, L1 cell-adhesion molecule L1CAM). However among REST 
identified targets there are also many genes not related to obvious neuron-specific 
functions, such as those involved in cellular metabolic processes (peroxisome and 
proteosome components) or in immune and inflammatory responses; additionally, there 
are genes that specify proteins that perform neuronal functions but are also required in 
non-neuronal tissues, including those involved in the regulation of cardiovascular tone 
(endothelial nitric oxide synthase, vasoactive intestinal peptide, atrial natriuretic peptide, 
brain natriuretic peptide, and KCNH2). [Bruce et al., 2004]. 
In addition there is an in vivo hierarchy in which distinct subsets of RE-1 interact with 
endogenous levels of REST, whereas others function as bona ﬁde transcriptional control 
elements only in the presence of elevated levels of REST. 
To identify the genes effectively regulated by REST in vivo efforts have turned to 
chromatin occupancy studies, by using new methods such as Serial Analysis of Chromatin 
Occupancy (SACO) and large-scale chromatin immunoprecipitation (ChIP Seq). 
Interestingly these studies revealed that the canonical RE-1 sequence results from a more 
complex motif, that can be both compressed or expanded, and that nucleotides 10 and 11 
of RE-1 were two of the least-highly conserved nucleotides across mammalian species: 
the new expanded and compressed motifs increased the number of potential REST-
binding sites. [Otto et al., 2007].  
The canonical REST-binding motif of 21 bp can be naturally subdivided into two 
nonidentical, nonpalindromic half sites; left and right half-site motifs are separated by a 
“spacer” sequence that increases the center-to-center distance from the canonical 11 bp 
to 16 to 19 bp, or decreases it by 1 bp to 10 bp (Figure 1.2) [Johnson et al., 2007]. 
Although REST could bind to half-sites of the RE-1 element, neither the left nor the right 
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half-site by itself is an effective repressor, indicating that half-site binding is not as strong 
or functional as full-site binding [Jothi et al., 2008].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: A) Canonical REST-binding motif: its left and right half sites have a center-to-center 
distance of 11 bp; B) WebLogo of noncanonical RE-1 with half-site distance of 17, showing the 
lack of conservation in the spacer nucleotides. 
 
While canonical sequence motifs facilitate strong REST binding and control functional 
classes of target genes that are common to all cell types, non-canonical motifs participate 
in weak interactions and control those targets which are cell- or tissue-specific [Bruce et al, 
Genome Research 2009]. 
Genome-wide analysis also revealed that variability in the occupancy of the RE-1 
elements could be a reflection of actual variation in REST binding to its target genes 
based on its affinity for the DNA element or based on the presence or absence of 
coactivators/corepressors of the process, or could result from nucleosome structure, or 
occupancy of adjacent sequences by other DNA-binding proteins. 
 
 
 1.2  REST AND COREPRESSORS 
 
In multipotent neural stem cells (NSCs) neuronal genes are repressed, but these cells have 
the capacity for subsequent expression in response to a developmental signal: the 
recruitment of chromatin modifiers to genomic loci by DNA binding protein is crucial 
for the establishment of epigenetic modifications, representing distinct stages of 
 
B 
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differentiation. REST provides a paradigm for elucidating the link between epigenetic 
mechanisms and neurogenesis: it orchestrates a set of epigenetic modifications that are 
distinct between ES cells, non-neuronal cells that give rise to neurons and those that are 
destined to remain as nervous system outsiders.  
REST-mediated gene repression is achieved by the recruitment of two separate 
corepressor complexes, mSin3 and CoREST. The amino terminal repressor domain of 
REST interacts with mSin3, a corepressor found in all eukaryotes that recruits two class I 
histone deacetylases (HDAC1 and HDAC2) and the retinoblastoma-associated proteins 
RbAp48 and RbAp46, thought to interact with histones [Grimes et al., 2000; Roopra et al., 
2000; Naruse et al., 1999]. The mSin3–HDAC complex, however, is associated primarily 
with a dynamic mode of repression that can alternate between repression and activation 
and therefore by itself would probably be inadequate for long-term silencing of neuronal 
genes. This conundrum was solved by the discovery of the corepressor CoREST, which 
interacts directly with the carboxy terminal repressor domain of REST [Ballas et al., 2001] 
and forms a complex containing HDAC1 and HDAC2, the histone H3 lysine 4 (H3-K4) 
demethylase LSD1, the chromatin-remodeling enzyme BRG1, the histone H3–
K9 methyltransferase  G9a and the methyl-CpG-binding protein MeCP2. 
In neuronal genes outside the nervous system REST recruits chromatin modifiers 
necessary for a long-term silencing: their activities are interdependent and occur in an 
ordered stepwise fashion to mediate efficient gene repression. First BRG1 is recruited by 
the C-terminal repression domain of REST, as part of the CoREST complex: it stabilizes 
REST binding on the RE-1 and allows REST to gain better access to its chromatin targets 
[Ooi et al., 2006]. Once associated with the chromatin, REST mediates repression 
through histone deacetylase, histone demethylase and histone methylase activities. 
HDACs deacetylate H3-K9 and H3-K14, a process that is required for subsequent 
demethylation of H3-K4 by LSD1 and dimethylation of H3-K9 by G9a: the addition of 
methyl groups to H3-K9 prevents the re-acetylation and is necessary for the subsequent 
recruitment of the Heterochromatin protein 1 (HP1), which mediates chromatin 
condensation.   
In long-term silencing this continued repression seems to be facilitated by the action of 
MeCP2 and of the histone H3–K9 methyltransferase SUV39H1: recent studies revealed 
that CpG dinucleotides spanning the REST binding site and surrounding regions of 
neuronal genes are methylated in differentiated non-neuronal cells [Ballas et al., 2005]. 
The overall effect of these modifications is manifested in the removal of several marks 
that are associated with transcriptional activation followed by their replacement with 
marks that are associated with transcriptional repression; moreover the recruitment 
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of silencing machinery by the REST–CoREST complex might result in the propagation 
of silencing across a large chromosomal interval, containing also neuronal genes that do 
not have their own RE-1, suggesting a relationship between higher 
order chromatin structure and patterns of gene expression (Figure 1.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figura 1.3: Schematic representation of long-term silencing mediated by REST. 
 
In pluripotent ES cells, instead, neuronal gene chromatin is programmed by the REST 
machinery to stay in an inactive but poised status, ready for subsequent activation: in this 
state REST is bound to the RE-1 motif and its corepressors, CoREST, mSin3, HDAC 
and MeCP2, are also present, but the RE-1 motif and the surrounding sequences in 
neuronal genes are not methylated. The absence of histone H3-K9 methylation and the 
enrichment of di- and tri-methylated H3-K4 coincide with actively transcribed genes and, 
in addition, RNA polymerase II (Pol II) is present on RE-1 sites in the 5’-untranslated 
regions of several neuronal genes, accompanied by very low levels of transcription. As ES 
cells proceed in the differentiation program towards neural progenitors, REST protein is 
 
Chapter 1- The transcription factor REST 
 9 
downregulated post-translationally; however terminal differentiation of progenitors to 
mature neurons occurs only with the transcriptional repression of the REST gene itself,  
causing the loss of the REST repressor complex from the RE-1 site of neuronal genes 
(Figure 1.4).  
Even if the transition from ES to neural stem/progenitor cell involves post-translational 
degradation of REST, its co-repressors, mSin3 and CoREST, persisted in the mature 
neurons: CoREST remains complexed with HDACs providing a platform for the 
dynamic assembly of repressor complexes required for plasticity even in absence of REST 
[Ballas et al., 2005]. However, since REST target genes exhibit different affinities, 
decreasing its concentration could result in differential gene expression: based on this 
observation REST-regulated genes can be divided in two classes. Class I genes are 
expressed by default, relying solely on the dissociation of the repressor complex from the 
RE-1 site for maximal expression; in contrast class II genes, typified by BDNF and 
Calbindin, show, in addition to the REST complex at the RE-1 site, the persistence of 
CoREST and MeCP2 (methyl-CpG-binding-protein-2) complexes on a distinct site of 
mCpGs in their promoters throughout differentiation and relatively low levels of 
transcription even during differentiation into cortical neurons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Schematic models for the differential regulation of REST and its target genes during 
development and in mature cortical neurons. (A) REST is downregulated by two different 
mechanisms during neural development. (B) Two classes of RE-1-containing genes are regulated 
differentially in postmitotic cortical neurons.  
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The molecular basis for differential recruitment of REST cofactors to RE-1 is the 
strength of the REST association: the “complex” sites, where all the corepressors are 
recruited, are usually more likely to conform to the strong RE-1 consensus motif, whereas 
the REST “alone” sites, where only REST is present, match less well with the consensus 
binding motif and form less stable complexes [Yu et al., 2011]. 
Epigenetic regulation is a compelling mechanism for controlling development events, 
which allows inheritance of distinct patterns of gene expression by chromatin 
modifications that do not involve changes in DNA sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Chromatin remodeling of neuronal genes by the REST complex.  
 
In concert with DNA methylation and non-coding RNA-mediated processes, histone 
modifications such as acetylation and methylation regulates gene expression: in general an 
increase of histone acetylation by HATs (Histone Acetyl Transferases) induces the 
remodelling of chromatin from a tightly to a loosely packed configuration, which 
facilitates transcriptional activation; conversely a decrease of histone acetylation by 
HDACs (Histone DeACetylases) yields a condensed chromatin structure and thus 
transcriptional silencing. Patterns of histone methylation are less strainghtforward: for 
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example histone H3 lysine 4 (H3-K4) methylation is a well-known marker of 
transcriptionally active chromatin, while methylated H3-K9 and H3-K27 mark 
transcriptionally inactive chromatin [Juliandi et al., 2010]. 
Histone acetylation is at least partially involved in the progression of ES cells to NSCs 
and neurons: ES cells appear to have a higher global level of histone acetylation than 
lineage-restricted stem cells and differentiated cells, which is consistent with the higher 
levels of transcription and more open chromatin configuration. Neuronal gene chromatin 
in ES cells is not completely silenced but is kept in a poised state: during neuronal 
differentiation the key switch for releasing neuronal genes from their poised state into an 
active one is the disappearance of REST by proteasomal degradation.   
Perturbation of HDAC activity may also contribute to the alleviation of the poised state, 
as HDAC inhibition results in an enhancement of neuronal differentiation of NSCs by 
upregulation of the proneuronal NeuroD gene (Figure 1.5). 
 
 
 1.3  STEMNESS AND PLURIPOTENCY 
 
In multicellular organisms the molecular basis for functional diversity of the various cell 
types is specific gene expression.  
Derived from the inner cell masses blastocysts, embryonic stem (ES) cells retain two 
peculiar characteristics: self renewal, that is the ability to generate exact copies of itself, 
and pluripotency, namely the capacity to differentiate into virtually all cell types of the 
body. The precise mechanisms that regulate ES self-renewal and pluripotency are largely 
unknown: current evidences suggest that ES cells maintain their pluripotent state by 
expressing a battery of transcription factors including Oct4 and Nanog. Oct4 regulates 
cell fate in a quantitative fashion and must be maintained at a critical concentration to 
sustain ES cells self-renewal, through interactions with other factors, such as Sox2 and 
FoxD3; in contrast Nanog, originally proposed as a transcription repressor of genes 
important for cell differentiation, primarily acts to activate those genes involved in 
maintaining stem cell pluripotency. Despite their role in maintaining stem cell 
pluripotency, little is known about how these transcription factors can regulate the activity 
of each other: it has been recently hypothesized that a negative feedback loop anchors 
Oct4, Nanog and FoxD3. In fact, Oct4 regulates Nanog activity in a dose-dependent 
manner, since Oct4 activates Nanog promoter when expressed below a steady-state and 
represses it at or above the steady-state concentration; FoxD3 is an activator of Nanog as 
well, apparently to counteract the repressive activity of Oct4 at the steady-state. On the 
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other hand Nanog and FoxD3 were found to activate Oct4 promoter, and Oct4 appears 
to serve as its own repressor to limit its own quantity, thus exerting a negative feedback 
pressure on the Oct4-Nanog-FoxD3 regulatory loop [Pan et al., 2006]. 
REST is expressed at high levels in embryonic stem cells, coinciding with the presence of 
critical regulators such as Oct4, Nanog and Sox2 and confirming that it has a unique role 
as a protector of self-renewal and pluripotency. It has been shown recently that in mouse 
ES cells REST is bound to the gene chromatin of a set of miRNAs that potentially 
interfere with the expression of critical self-renewal regulators such as Oct4, Nanog and 
Sox2 [Singh et al., 2008]. At least one of these miRNAs, miR-21, markedly decreased the 
self-renewing capacity of ES cells: interestingly earlier studies indicated that miR-21 
expression was higher in differentiated compared to undifferentiated ES cells. Take 
together these data indicate that REST regulates the self-renewal of ES cells via repressing 
the transcription of a specific miRNA, miR-21, which suppresses self-renewal through the 
loss of expression of the critical regulators Oct4, Nanog and Sox2. It is noteworthy that 
Oct4, Nanog and Sox2 were found to co-occupy REST promoter/enhancer sequences, 
apparently as an activator complex, suggesting that REST can be a major component of 
the Oct4-Nanog-Sox2 network in ES cells [Zhou et al., 2007]. 
 
 
 1.4  REST AND NEUROGENESIS 
 
Neural stem cells (NSCs) are a subset of undifferentiated precursors that retain the ability 
to proliferate and self-renew, and have the capacity to give rise to neuronal and glial 
lineages in the nervous system: neurogenesis, initiated from NSCs and resulting in 
functional new neurons, is a fundamental process for both embryonic development and 
adult brain plasticity. Neuron differs from any other cells by containing a specific set of 
proteins that are critical for execution of specialized functions and are encoded by genes 
that must be expressed in a neuron-specific manner: the process of creating  a properly 
functional neuron, including NSCs self-renewal and fate specification, neuronal migration, 
maturation and integration, is regulated by the dynamic interplay between transcription 
factors, epigenetic control, miRNA regulators and cell-extrinsic signals from the niche 
where stem cells reside. 
Generally thought of as positive regulators of transcription, one can imagine that by 
recognizing binding sites in the promoter of various markers on neuronal activity and 
inducing their expression, transcription factors encourage immature cells along the path 
of neuronal differentiation; a deeper consideration of neurogenesis however, reveals that 
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differentiation is as much dependent on upregulation of proneural genes as on inhibition 
of repressors. A master switch for differentiation is NeuroD2, which inhibits the 
expression of REST, thus linking two important factors within the transcriptional 
landscape of a maturing neuron. In particular NeuroD2 downregulates REST 
transcription indirectly, through the activity of the repressor Zfhx1a [Ravanpay et al., 
2010]. 
Regulation of REST plays a fundamental role in the progression of pluripotent cells to 
lineage-restricted neural progenitors: it functions very effectively as a transcriptional 
repressor at a distance and is able to repress transcription despite location or orientation 
of the binding site within a gene.  
REST is believed to be a major transcriptional repressor of neurogenesis and activation of 
its target genes was found to be sufficient to convert NSCs cells to neuronal phenotypes 
[Su et al., 2004]: Sox4 and Sox11 are transcriptional activators that can induce the 
expression of neuronal markers in self-renewing precursors and are vital for the 
establishment of neuronal protein expression. The expression of Sox4/11 is directed to 
post-mitotic neural cells by a combinatorial action of pro-neural proteins and REST: in 
fact in addition to its ability to directly repress neuronal gene enhancers, REST also 
appears to prevent precocious expression of neuronal proteins in undifferentiated neural 
cells, through its capacity to suppress the expression of Sox4/11 [Bergsland et al., 2006].  
While it is important to understand how positive markers of a particular cells fate are 
induced during differentiation, it is also important to learn how other cellular fates are 
actively repressed such that a cell does not get lost along the differentiation axis. 
 
 
1.5  ADULT NEUROGENESIS   
 
When REST binding to various targets in ES, neural stem and hippocampal cells was 
evaluated it was observed that distinct REST complexes occupied RE-1 elements at 
various target genes, supporting the hypothesis that the interaction of REST with its 
target genes was distinct in these cell types. Adult neurogenesis, a multistep process 
supporting neuronal turnover throughout life, represents a natural paradigm for 
maintaining tissue homeostasis, from a resident population of quiescent NSCs. In the 
mammalian hippocampal subgranular zone and subventricular zone that lines the lateral 
ventricles, both early and late events of adult neurognesis are governed by multiple 
signalling pathways and neurotransmitter signalling systems.  
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Figure 1.6: Schematic representation of REST expression and action during neurogenesis.  
 
During the course of adult neurogenesis, NSCs get through a number of stages, starting 
from cells that retain the ability to proliferate, going to slowly dividing “quiescent” NSCs, 
transit-amplifying progenitors and neuroblasts. It has been difficult to determine whether 
REST plays distinct roles during embryonic and adult stages of neurogenesis: it has been 
demonstrated that REST is required to maintain the adult neural stem cell pool and 
orchestrates stage-specific differentiation [Gao et al., 2011]. Consistent with REST being 
a transcriptional repressor in non-neuronal cells, its expression has been verified in 
astorcytes and oligodentrocytes; on the contrary, loss of REST in NSCs leads to the exit 
of quiescence and loss of neurogenic capacity, since it resulted in de-repression of a 
cohort of REST target genes and precocious neuronal differentiation (Figure 1.6). 
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1.6  REST AND ncRNAs 
 
To understand the CNS, scientists have investigated a variety of molecules, including 
proteins, lipids, and various small molecules: however one large class of molecules, 
noncoding RNAs (ncRNAs), has been relatively unexplored. ncRNAs function directly as 
structural, catalytic, or regulatory molecules, rather than serving as templates for protein 
synthesis. Examples include the small nucleolar RNAs (snoRNAs), which guide site-
specific RNA modifications, the miRNAs, which post-transcriptionally repress gene 
expression, and the rasiRNAs (repeat associated small interfering RNAs), which direct 
heterochromatin formation at centromeres. 
MicroRNAs (miRNAs) are endogenous ∼21-nt single-stranded RNAs processed by Dicer, 
a double-stranded RNA(dsRNA)-specific endonuclease, from one arm of ∼ 70-nt 
stemloop precursors (pre-miRNAs); pre-miRNAs, in turn, are excised from longer 
primary transcripts (pri-miRNAs) by another dsRNA-specific endonuclease named 
Drosha. miRNAs function as negative regulators of gene expression by  base-pairing with, 
in many cases, the 3’-untranslated region (3’-UTR) of target mRNAs in the form of 
ribonucleoprotein complexes, known as RNA-induced silencing complexes (RISCs). 
Because the interaction between a miRNA and its target requires only partial 
complementarity, one miRNA could regulate hundreds of  mRNAs [Cao et al., 2006].  
Many mammalian miRNAs are expressed in a temporal and/or tissue-specific manner. 
The brain, in particular, hosts a diverse collection of miRNAs; approximately 70% of 
experimentally detectable miRNAs are expressed in the brain, and during brain 
development, the expression levels of some miRNAs change dynamically.  
High-throughput studies revealed that REST might have links to some ncRNAs; although 
they were previously known to be involved in the regulation of neurogenesis, the 
underlying mechanism remained unclear, until recent researches added some of these 
molecules to the portfolio of REST targets.  
miR-124 is the most abundant miRNA in the adult mammalian brain, accounting for 
25%–48% of all brain  miRNAs: conserved sequences complementary to the seed region 
of miR-124 are prevalent in the 3’-UTRs of mammalian transcripts, with more than 1100 
genes being predicted to be putative targets of miR-124. During neurogenesis miR-124 
expression is undetectable or expressed at low levels in progenitor cells and is  
upregulated in differentiating and mature neurons: previous studies demonstrated that 
overexpression of miR-124 in HeLa cells led to decreased expression of many non-
neuronal genes, to reflect a gene expression program more similar to that of neuronal 
cells [Lim et al., 2005]. Blocking miR-124 activity in mature neurons leads selectively  to 
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increased levels on non-neuronal transcripts. In addition one of the earliest miRNAs 
identified as a direct REST target based on binding studies and expression analysis was 
miR-124, revealing that the establishment and maintenance of neuronal identity requires 
both derepression of REST-regulated genes as well as post-transcriptional downregulation 
of non-neuronal transcripts by a miRNA, that is also under REST control: in NSCs and 
non-neuronal cells REST represses the expression of the proneural miR-124, preventing 
neurogenesis and facilitating the continued expression of non-neural genes [Conaco et al, 
2006]. Upon onset of neuronal differentiation declining REST levels associate with global 
de-repression of neuronal genes and miR-124, which leads to en-masse downregulation of 
non-neuronal transcripts: together these events alter the balance in favour of the neuronal 
phenotype. Moreover miR-124 may act in turn by silencing REST and switching on 
neuron-specific splicing by targeting PTBP1, a repressor of pre-mRNA splicing in non-
neuronal cells, allowing the transition form a progenitor state to a differentiated neuronal 
phenotype (Figure 1.7). 
 
 
 
Figure 1.7: Overview of REST function in ES cells self-renewal and neurogenesis in neural and 
non-neural cells. In ES cells REST represses the expression of miR-21, a negative regulator of 
proteins involved in self-renewal including Sox2, Nanog and Oct4. In the absence of miR-21, the 
expression of Sox2, Nanog and Oct4 in ES cells is maintained, which in turn feeds back and 
activates REST expression and contributes to self-renewal. In non-neural cells, the REST/SCP1 
complex represses the expression of neuronal genes and the pro-neuronal miR-124. In neurons, 
REST is absent and, consequently, miR-124 is expressed: this not only promotes neuronal gene 
expression, but also represses non-neuronal gene expression.  
 
Thus the intricate transcriptional and post-transcriptional regulatory controls for neuronal 
gene expression are highly integrated and mediated, in part, by double-negative feedback 
loops between REST and the miRNAs. 
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Since these initial reports, the list of putative REST-target miRNAs has grown 
substantially: computational analyses, genome-wide binding studies and ChIP analyses 
have collectively identified several neuron-specific miRNAs, including miR9-1, miR9-3, 
miR-29a/miR-29b, miR-95, miR-132, miR-133, miR-135b, miR-139, miR-153, miR-218-
212, miR-346, miR-375 and miR-455, to have the potential for regulation by REST. 
miR-9 has been proposed as one of the crucial regulators of neuronal development, 
physiology and pathology in several organisms: in mammals it is induced upon embryonic 
stem cell neuronal differentiation and blocking its function during this process decreases 
neuronal differentiation at the expense of astrocytes. In addition it has onco-suppressor 
properties, with a crucial role in repressing cell proliferation of human neuroblastoma and 
medulloblastoma. In proliferating cells, where it is highly expresses, REST is bound to the 
miR9 promoter preventing transcriptional activity; upon neuronal differentiation REST 
dismissal and the concomitant phosphorylation of the already bound neuronal activator 
CREB activate transcription. Noteworthy REST mRNA is also targeted by miR-9 during 
neuronal differentiation [Laneve et al., 2010]. 
Although the disappearance of REST repressor complex in differentiating neurons leads 
to the expression of RE-1-containing genes during development, a reduced presence of  
REST has been observed even in adult neurons: one mechanism to cancel its repressor 
effect has been demonstrated by the discovery of a nuclear localized small modulatory 
RNA (smRNA), which appears transiently at the early period of neuronal differentiation 
in cultured adult neural stem cells. This double-stranded smRNA is about 20 bp in length, 
carrying the same sequence as RE-1/NRSE and hence designated as RE-1/NRSE-
smRNA [Kuwabara et al., 2004]. RE-1/NRSE-smRNA binds REST as well as the RE-1 
dsDNA: the dsRNA captures REST as a decoy and release the genome from repression. 
Binding the RE-1/NRSE-smRNA to REST prevents the association of corepressor 
proteins, such as HDACs and methyl-DNA binding proteins, and, possibly through 
additional mechanisms, converts REST to a transcriptional activator. After the RE-
1/NRSE-smRNA appears, transcriptional activation of RE-1-containing genes is 
triggered.  
Not surprisingly, perturbations of REST activity and related deregulation of ncRNAs 
have also been implicated in the molecular pathophysiology of diverse disorders, that 
range from cancer to neurodegenerative and neurodevelopmental diseases. 
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1.7 REGULATION OF REST TRANSCRIPTION 
 
Despite the extensive number of studies to elucidate the function of REST, relatively little 
has been done to determine how expression of REST gene itself is regulated. Analysis of 
the human, mouse and rat gene structures has shown that the exon and intron structure is 
conserved and that REST transcripts begin from one of three alternatively used 5′ exons 
(indicated by black boxes in Figure 1.8). The presence of three alternatively used 5′ exons, 
called exon A, B and C, suggests that REST contains at least three promoters: promoter 
A has been shown to be the most active in non-neuronal cells, while promoter B in 
neuronal cells. Promoter C, on the contrary, showed no activity in neuronal cells and only 
weak activity in non-neuronal and neural progenitors, suggesting that it acts as a potent 
silencer of the other two REST promoters: these findings suggest that the cell-specific 
regulation of any of the three REST promoters by adjacent or distal enhancers or 
repressors is likely to depend on the action of trans-acting factors that bind to these 
regions in particular cell types.  
 
 
 
 
 
Figure 1.8: Schematic representation of REST promoter region. 
 
Human and mouse REST promoters have multiple transcription start sites and contain 
GC boxes that recruit the Sp1 family of transcription factors; other transcription factors 
involved in the regulation of REST expression are PBX, AP-1, CREB and Sox 
[Koenigsberger et al., 2000]. Moreover REST expression is regulated by the Wnt 
signalling pathway which is important in many tissues, particularly during development: 
ectopic expression of Wnt1 or β-catenin induces REST in chicken embryonic spinal cord 
through a T-cell factor (TCF)-binding site, present in exon A and conserved between 
humans and mice. REST was also identified as a target for the transcription factors 
Nanog and Oct4 in mouse and human embryonic stem cells and in fact both Nanog and 
Oct4 have been shown to be simultaneously bound to a region about 2 kb from exon A. 
Chromatin immunoprecipitation analysis of the REST promoter revealed also the 
presence of an HDAC complex that contained mSin3, CoREST and MeCP2. Intriguingly 
the Retinoic Acid Receptor (RAR) and its corepressor, N-CoR, were part of this repressor 
complex, bound to a region containing a Retinoic Acid Response Element (RARE), 
located 400 bp upstream of the transcriptional start site [Ballas et al., 2005]. During 
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terminal differentiation an unliganded RAR repressor complex is recruited to a RARE site 
located upstream from the transcriptional start site, causing the repression of REST 
transcription and exit from the cell cycle and the onset of terminal differentiation. 
Although REST mRNA levels are known to change in response to several stimuli, it is 
not known whether this is mediated by changes in transcription or by changes in mRNA 
turnover, possibly mediated by miRNAs. 
 
 
1.8 REST DEGRADATION 
 
The transition from stem or progenitor cell to a post-mitotic neuron requires disarming 
REST: several groups have demonstrated that REST levels are significantly different in 
ES cells, NSCs and non-neural cells. In particular REST levels appear to be regulated by 
transcriptional and post-transcriptional mechanisms depending upon the cell type (Figure 
1.9): during cortical differentiation, post-translational degradation of the REST protein 
precedes both its dismissal from RE-1 sites and transcriptional inactivation of 
the REST gene itself.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Regulation of REST by transcriptional and post-transcriptional mechanisms. REST is 
expressed at high levels in ES cells; a decline is observed during their specification into NSCs. In 
neural progenitors REST is transcriptionally downregulated by the RAR; in non-neural cells 
REST function is also regulated by changes in its subcellular localization mediated by the 
Huntingtin/RILP complex.  
 
REST was identified as a substrate for a member of the Skp1-Cullin1-F-box (SCF) β-
TrCP family ubiquitin ligases E3s and in fact REST levels are regulated through its 
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proteasomal degradation, involving β−TrCP E3 ubiquitin ligase. SCFβ−TrCP binds and 
ubiquitinates its substrates through a conserved phospho-degron (DSGXXS), in which 
the serine residues are phosphorylated: REST has two adjacent yet distinct similar motifs 
at its C-terminus and degron-mutant REST was shown to be substantially more stable 
that wild-type REST, thus attenuating differentiation [Westbrook et al., 2008].  
Any disruption of the cell-cycle-, β-TrCP-dependent regulation of REST in non-neuronal 
cells contributes to genetic instability; since REST is a transcriptional repressor, its 
degradation in the G2 phase of the cell cycle might be necessary to de-repress genes 
involved in mitosis. In particular SCFβ−TrCP-dependent degradation of REST during G2 is 
required for the fidelity of mitosis, since it allows transcriptional de-repression of Mad2, 
an essential component of the spindle assembly checkpoint [Guardavaccaro et al., 2008]. 
Mutant REST, unable to bind β-TrCP, inhibiting Mad2 expression causes faulty 
activation of the spindle checkpoint, with specific defects such as shortened mitosis, 
premature sister-chromatid separation, chromosome bridges and mis-segregation in 
anaphase. 
REST proteolysis must be accurately controlled to avoid subjecting neuronal tissues to 
cancer risk: in fact increased REST levels resulting from its over-expression, as observed 
in human neuronal tumours, would both inhibit differentiation and generate 
chromosomal instability, two mechanisms that contribute to tumour development. On 
the other hand hyper-activation of the pathways priming REST degradation may be 
oncogenic in epithelial tissues, thus serving as novel therapeutic targets in cancers with 
compromised REST function. 
However reciprocal mechanisms that stabilize REST are needed. The deubiquitylase 
HAUSP (Herpesvirus-Associated-Ubiquitin-Specific Protease 7) antagonizes β-TrCP-
mediated ubiquitylation of REST and prevents NSCs differentiation: the balance between 
ubiquitylation and deubiquitylation may determine the net REST protein levels, defining 
the maintenance of stemness or initiation of neuronal differentiation. When the HAUSP-
mediated deubiquitylation overrides β-TrCP-mediated ubiquitylation REST is stabilized 
to suppress differentiation and promote NSCs maintenance; in contrast, when β-TrCP-
mediated ubiquitylation exceeds HAUSP-mediated deubiquitylation, REST is targeted for 
degradation, which promotes cell differentiation by releasing repression of differentiation-
associated genes [Huang et al., 2011].  
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1.9  REST INVOLVEMENT IN SEVERAL PATHOLOGIES 
 
REST was found to regulate several genes that may impact important biological processes: 
most of the understanding about the role of REST in normal adult tissue comes from 
studies of disease states, in which REST function is altered. 
Increased levels of REST were found in rat hippocampal and cortical neurons in response 
to epileptic seizures and ischaemia: these insults de-repress REST mRNA and protein in 
dying neurons, and this was suggested to be a critical mechanism of insult-induced 
neuronal-death [Calderone et al, 2003]. REST was also found to repress the µ-opioid 
receptor in neuronal cells, and thus may have a neuroprotective role in opium addiction. 
Similarly, REST was found to repress the serotonin 1A receptor, which is implicated in 
depression and anxiety [Lemonde et al., 2004]. 
Potential roles for REST and its target genes have also been implicated in the 
pathogenesis of Huntington’s disease. REST and huntingtin protein were found to form a 
complex that forced REST to localize in the cytoplasm in normal neuronal cells, 
inhibiting its function; in patients with Huntington’s disease this interaction was ablated 
by the huntingtin mutation, resulting in the translocation of REST in the nucleus and 
causing blockade of neuronal gene expression. One of REST targets is the neuronal 
survival factor BDNF (Bran Derived Neurotrophic Factor), low levels of which are 
thought to contribute to neuronal degeneration [Zuccato et al., 2003]. 
Among non-neuronal tissues REST was found to be present in normal ventricular 
myocites, having a role in maintaining normal cardiac structure and function: in cardiac 
dysfunctions and arrhythmogenesis REST expression is inhibited, resulting in the 
expression of fetal cardiac genes. 
Alterations of REST are evident even in several tumors, although it appears to be 
achieved through diverse mechanisms: several genomic alterations have been identified in 
REST coding region, all located in exon 3, which may cause changes in the biochemical 
properties of the REST protein, and affect its binding to target DNA.  
In some neural cells REST can behave as an oncogene: increased REST expression has 
been implicated in neuroblastomas and medulloblastomas. Medulloblastoma is one of the 
most malignant pediatric brain tumors and is believed to arise from undifferentiated 
neuroectodermal stem cells in the cerebellum: these cells have a primitive embryonal 
phenotype and show the capacity for divergent differentiation. To date the mechanism of 
medulloblastoma tumorigenesis is still unknown. Medulloblastoma cells express REST at 
high levels, compared with either neuronal progenitor cells or fully differentiated neurons, 
accompanying a failure to differentiate: in contrast to the reduction of REST during 
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normal neuronal differentiation, this generates proliferating cells where many target genes 
characteristic of post-mitotic neurons are silenced. A recombinant transcription factor, 
REST-VP16, constructed by replacing the repressor domains of REST with the activation 
domain of the herpes simplex virus protein VP16, can compete with endogenous REST 
for DNA binding, activate REST target genes and trigger apoptosis through the activation 
of caspase 3 cascade [Fuller et al., 2005]. However medulloblastoma tumorigenesis starts 
when two conditions occur in NSCs: lack of differentiation, as a result of REST 
expression, and overall increased proliferation, as a result of the Myc oncogene expression 
[Su et al., 2006].  
On the other hand a variety of tumors, including those arising in breast, ovary, lung and 
colon, activates expression of neuron-specific genes: the expression of neuronal genes out 
of their normal context causes the permanence of malignant cells in the cell cycle. 
Abnormal expression of neuronal genes results from the loss of REST activity, which 
normally represses their expression and leads to oncogenic conversion of these cells, 
perhaps through the aberrant expression of REST target genes, resulting in an abnormal 
neuroendocrine phenotype. Moreover inactivating mutations of the REST gene were 
identified in colorectal cancer: deletions of human chromosome 4q12, on which REST is 
located, are frequent events in this type of cancer. A frameshift mutation in the REST 
coding region, resulting in a premature termination codon in the center of the coding 
sequence and yielding a truncated protein that lacks the C-terminal repression domain, 
was also identified in primary colon adenocarcinoma: this dominantly acting truncation is 
capable of transforming epithelial cells through an increased of PI(3)K-dependent 
signalling, in both intensity and duration [Westbrook et al., 2005]. Finally, reduced REST 
function caused by increased expression of a splice variant that lacks some of the DNA-
binding domain and the C-terminal repression domain has been associated with small-cell 
lung carcinomas (SCLCs): this event leads to the expression of neuronal markers, like L1-
cell adhesion molecule (L1-CAM) and neural cell adhesion molecule (NCAM), enhanced 
cell proliferation and anchorage independent cell growth [Kreisler et al., 2010]. In some 
instances the inappropriate expression of neural genes elicits an autoimmune response 
that culminates in neurological disorders, collectively known as Paraneoplastic Neurologic 
Degenerations (PNDs). 
Thus, depending on the cell type REST may both have tumorigenic and tumor-
suppressor effects, which would indicate that REST is a major biological regulator of 
normal and abnormal development: in epithelial cells REST functions as a tumor-
suppressor, while in differentiating or differentiated neuronal cells REST repressor 
activity has an oncogenic function. 
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2. PROTEIN GLYCOSYLATION 
 
Fundamental to the normal functioning of a single cell or multicellular organism is 
control over their entire metabolism. This control is important for the central dogma of 
molecular biology that DNA leads to RNA, which in turn leads to protein. In this context, 
control is related to decision-making about gene expression, transcription and translation.  
In eukaryotes, the process of going from DNA to functional protein usually consists, at 
the most basic level, of at least six discreet steps: transcription, splicing, polyadenylation, 
transport, translation, and post-translational modification. At the level of RNA, 
alternative transcriptional start sites and alternative mRNA splicing may increase 
complexity; regulation of mRNA levels and differential protein stability can modulate  
protein levels. External stimuli also contribute to the uniqueness of a cell’s proteome 
through specific expression patterns. Although the most common way that diversity is 
generated in proteins is, of course, alteration of the order and composition of their 
constituent amino acids, additional diversity is generated by covalent modification of 
amino acids by the addition of post-translational modifications (PTMs), such as 
phosphates or glycans, or by disulfide bond formation. While only 20 amino acids are 
used in protein synthesis, as many as 140 different amino acids are found in proteins due 
to covalent post-translational modification [Vosseller et al., 2001]. 
PTMs are ubiquitous in the cell: they regulate the function of proteins and provide a 
mechanism for increasing the diversity of protein structures. In addition, such 
modifications may result in the localization of proteins to specific cellular organelles, with 
incorrect targeting being associated with a number of diseases. It is often believed that 
PTMs may regulate protein activity by changing the protein surface and by introducing 
new functional groups that act as a signaling tag for binding to other molecules. These 
modifications may also modulate the thermodynamic and kinetic features of proteins (e.g. 
stability, structural flexibility, and folding rate): thus, they efficiently and economically 
increase the complexity and dimensions of the primary gene products. Various PTMs 
have been shown to affect protein biophysics [Shental-Bechor and Levy, 2009]. For 
example, phosphorylation contributes with negative charges to the protein surface and 
can induce conformational changes, while methylation and acetylation mask charges and 
play an important role in protein–DNA interactions.  
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2.1 GLYCOSYLATION 
 
Among the various PTMs the most common is the complex process of glycosylation, that 
is the covalent attachment of one or more carbohydrates, also termed “glycans”, that 
occurs  during or after the process of protein synthesis. It is a complex process that 
commonly involves different monosaccharides, attached to any of eight types of 
aminoacid residues and is assisted by many enzymes: although the number of different 
types of glycosidic bond seems to be increasing at a frenzied rate, N- and O-linked glycans, 
where the amino acid residues involved are asparagine and serine or threonine, still 
remain the most abundant. Glycosylation is possible involving about 1% of human genes 
[Lowe and Marth, 2003]; furthermore, according to estimates based on the SwissProt 
database, more than one half of all proteins are glycosylated [Apweiler et al., 1999]. 
Glycosylation imparts many properties to proteins and might be important for their 
function. One of the initial functions of glycosylation in a given protein is to direct the 
protein to the appropriate cellular location: for example, many lysosomal proteins harbor 
a mannose-6-phosphate moiety that behaves as a signaling molecule. In addition, the 
calnexin–calreticulin cycle in the endoplasmic reticulum (ER), a quality-control 
mechanism that prevents misfolded proteins from being transported further, is dependent 
upon the N-glycosylation of the proteins in question (see paragraph 2.3.1). Among the 
roles ascribed to glycosylation, the most important is the recognition of glycosylated 
proteins by carbohydrate-binding proteins called lectins: the lectin–sugar interaction 
mediates several important processes, including host-cell recognition by pathogens. A 
benchmark example is the docking of the influenza virus on host cells by binding to the 
terminal sialic acids of the host-cell surface glycoproteins. Glycosylation can modulate 
physico-chemical properties of proteins, such as thermal stability and hydrophobicity. In 
most instances, glycosylation of a protein begins even as the protein is being synthesized, 
suggesting that glycosylation might have an important role in protein folding and 
oligomerization: inhibition and/or suppression of glycosylation often results in 
aggregation or misfolding of proteins. Also, certain glycosylation sites in a given protein 
are more important compared with other sites, suggesting that glycosylation exerts local 
effects on protein conformation in addition to more global effects.  
Glycoproteins have been found in essentially all living organisms, ranging from eubacteria 
to eukaryotes, from unicellular organisms, such as yeast and trypanosomes, to the highly 
differentiated tissues of the animal and plant kingdoms. Thirteen different 
monosaccharides and eight amino acid types participate in these bonds so that at least 31 
sugar–amino acid combinations exist: the aminoacids involved in glycosylation process 
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known so fare are asparagine, arginine, serine, threonine, proline, hydroxyproline, 
tryptophan and tyrosine. Formation of the sugar–aminoacid linkage is a crucial event in 
the biosynthesis of the carbohydrate units of glycoproteins. The modification of proteins 
through enzymatic glycosylation is an event that reaches beyond the genome and is 
controlled by factors that differ greatly among cell types and species. Many elaborate 
glycosylation routes have been identified in various organisms that lead to the mature 
carbohydrate units on glycoproteins that are secreted by cells or become components of 
its membranes, cytoplasm, or nucleus [Spiro, 2002]. 
 
 
2.2 FOLDING OF GLYCOPROTEINS 
 
Glycosylation may affect many protein activities: it has been shown to facilitate folding 
kinetics and to affect the biophysical properties of proteins, which are a consequence of 
the underlying energy landscapes that govern their folding. It may also modulate a 
protein’s characteristics by affecting differently the energetics (enthalpy or entropy) of the 
unfolded and/or folded state. However, the role of glycans in attaining the correct fold is 
ambiguous. There is evidence for protein misfolding and aggregation in the absence of 
glycans; in other cases, however, elimination of some or all glycans has no effect on 
folding or protein function, implying that some glycosylation sites are more crucial to 
protein folding or function than others and that the effect of glycans on folding is likely 
to be local. 
A protein folds by navigating through an energy landscape that is globally funneled 
toward a structurally defined native state: the funneled nature of energy landscapes is a 
product of the evolutionary selection of sequences that are minimally frustrated, in that 
they have fewer interactions that are in conflict with the native state and thus exhibit 
relatively high conformational preferences. The defining event in the biogenesis of 
peptide-linked oligosaccharides is clearly the formation of the sugar–aminoacid bond: this, 
in most instances, determines the nature of the carbohydrate units that will subsequently 
be formed by the cellular enzymatic machinery, which in turn influences the protein’s 
biological activity. A multitude of diverse sugar–aminoacid combinations have been 
described.  
Several factors may govern the effect of glycosylation on the protein energy landscape 
and, consequently, on the biophysical characteristics of the protein. From the 
oligosaccharide perspective, the size of the glycans, their flexibility and structure, the 
number of branches, may affect the properties of the protein. From the protein 
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perspective, the location and chemical surroundings of the glycosylation sites, as well as 
the number of occupied glycosylation sites, may influence the effect of glycosylation on 
the protein. Quantifying how glycosylation can affect protein biophysics by modulating 
the protein’s energy landscape may formulate a ‘glycosylation code’: deciphering such a 
molecular code, however, is a difficult task for two main reasons. First, oligosaccharides 
are complex and heterogeneous systems, and structurally more complex than proteins 
(although they lack folding capability), since they can form various topological trees via 
various linkage positions, while the proteins are linear polymers. Second, the number of 
glycoproteins having a resolved 3D structure is very limited (while ~50% of all proteins 
are glycosylated only about 3,5% of the proteins in the Protein Database (PDB) carry 
covalently bound glycan chains and even fewer have full structure of the glycans), mainly 
because the conformational heterogeneity of the oligosaccharides often inhibits their 
crystallization or makes them barely visible in X-ray crystallography or nuclear magnetic 
resonance spctroscopy [Apweiler et al., 1999]. 
Glycans, which are bulky hydrophilic polymers, often increase solubility of the protein to 
which they are attached as well as its resistance to proteolysis; moreover, the covalent 
binding of glycans to protein surfaces may enhance their thermodynamic and kinetic 
stability. Greater thermodynamic stability is expressed by an increase in the melting 
temperature of the glycosylated protein or in the free energy difference between the 
unfolded and folded state ensembles, being greater for the glycosylated protein than for 
its nonglycosylated wild-type counterpart.  
Many glycoproteins contain several glycosylation sites, which may be occupied 
alternatively or concomitantly: it is therefore of great interest to understand how the 
biophysical characteristics of glycoproteins are affected by the number of oligosaccharides 
covalently attached to the proteins and whether there is a cooperative effect between the 
various glycans: the degree of folding increases significantly with the degree of 
glycosylation, by about 4% per added glycan. The attachment of a sugar can modulate 
protein stability depending on the position of the glycosylation site: glycosylation at a 
more-structured region results in destabilization, while glycosylation at a more-disordered 
region increases protein stability. The degree of glycosylation also affects protein folding 
kinetics: the unfolding rate decreases as the degree of glycosylation increases, indicating 
kinetic stabilization of the protein [Shental-Bechor and Levy, 2009]. In some structural 
studies of glycoproteins, specific interactions between the sugar and aminoacids of the 
folded protein were observed: the stabilization effect in these cases is enthalpic in origin 
[Hanson et al., 2009]. Earlier studies suggested that the origin of glycoprotein’s thermal 
stabilization is largely entropic, rather than enthalpic, proposing a ‘chaperone-like’ activity 
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of glycans [Wang et al., 1996]. Both the enthalpy and the entropy of the folded state 
decrease as the degree of glycosylation increases: the reduced entropy induced by 
glycosylation is caused by the suppression of protein fluctuations in the folded state while 
its conformation remains unchanged. The glycans can therefore be viewed as imposing 
pressure on the protein that reduces the flexibility of the folded state: the rigidified 
structure induced by glycosylation is characterized by tertiary interactions that are more 
localized in their optimal distances, thus reducing enthalpy. 
These evidences demonstrate that there is a fine cross-talk between the carbohydrate 
moiety and the peptide backbone of a given protein: mutating the glycosylation sites of a 
protein in vivo reduces the efficiency of folding and increases degradation [De Virgilio et 
al., 1999]. 
 
 
2.3 N-GLYCOSYLATION 
 
N-linked glycosylation results from the attachment of the glycan to an asparagine (Asn) 
side chain of the protein: five different N-glycan linkages have been reported, of 
which N-acetylglucosamine to asparagine (GlcNAc-β-Asn) is the most common. The 
process occurs on the lumenal side of the endoplasmic reticulum (ER) membrane while 
the protein moiety is being synthesized on ER-bound ribosomes and is translocating 
through the translocon in the ER membrane: the fact that N-glycosylation starts during 
protein synthesis, when the glycan is added to the still unfolded protein, indicates that it 
may assist in obtaining the correct fold, following the recruitment of the lectins calnexin 
and calreticulin. Processing of the N-glycans is coupled with the fates of glycoproteins in 
cells: they play a crucial role in keeping order in the ‘protein society’ by controlling folding, 
transport, and degradation of their carrier polypeptide chains [Roth et al., 2010].  
The biosynthesis of all eukaryotic N-glycans begins on the cytoplasmic face of the ER 
membrane with the transfer of N-acetylglucosamine-phosphate (GlcNAc-P) from UDP-
GlcNAc to the lipid-like precursor dolichol-phosphate (Dol-P) to generate dolichol-
pyrophosphate N-acetylglucosamine (Dol-P-P-GlcNAc). Fourteen sugars are sequentially 
added to Dol-P before en bloc transfer of the entire glycan to the protein that is being 
synthesized and translocated through the ER membrane by the Sec61 translocon complex: 
subsequently an oligosaccharyltransferase (OST), which is a hetero-oligomeric membrane 
protein, in association with a translocon in the lumen of the ER, catalyzes the transfer of 
the Glc3Man9GlcNAc2 procursor from dolichol pyrophosphate to the Asn residue in the 
consensus sequence. The protein-bound N-glycan is subsequently remodeled in the ER 
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and Golgi by a complex series of reactions catalyzed by membrane-
bound glycosidases and glycosyltransferases: these reactions encompass the sequential 
removal of all three glucose residues of the branch A and some of the mannose residues 
of the branch B and C, as well as branch A (Figure 2.1). The glycan processing leads to 
the formation of high-mannose, hybrid or complex type oligosaccharides. Oligomannose 
glycans are composed of solely mannose residues attached to the core Man3GlcNAc2; in 
complex glycans, instead, “antennae” initiated by N-acetylglucosaminyltransferases 
(GlcNAcTs) are attached to the core; hybrid glycans contain only mannose residues 
attached to the Manα1–6 arm of the core and one or two antennae on the Manα1–3 arm. 
[Cummings, 1992]. The glycans and their final processing vary with the protein and the 
species in question. For example, although mammalian and yeast systems start with the 
same kind of N-glycans that undergo glucose and mannose removal by glucosidase I or II 
and α-mannosidase I, yeast systems go on to form high-mannose structures, whereas 
mammalian N-glycans lose mannose residues to form Man5GlcNAc2-Asn by the action of 
further mannosidases [Mitra et al., 2006].  
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Structure of the Glc3Man9GlcNAc2 precursor linked to an Asn residue. 
 
In addition, a strict consensus sequence, Asn-Xxx-Ser/Thr, was postulated, where Xxx 
can be any aminoacid except proline (Pro): it has been proposed that the Ser or Thr is 
required for a hydrogen-bond donor function in enzyme binding and in oligosaccharide 
transfer; the negative effect of Pro as the Xxx aminoacid has been attributed to its 
interference with the ability of the peptide chain to adopt and stabilize a loop 
conformation [Bause E., 1983]. 
Variation in the degrees of saturation at available glycosylation sites results in 
heterogeneity in the mass and charge of glycoproteins; each glycosylation site may further 
exibit variable occupancy and each occupied site, in turn, exhibits heterogeneity in the 
attached glycan structures. The composition and structure of the carbohydrate attached to 
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a glycoprotein are determined by the glycosylation machinery available in a specific cell 
type; there changes can significantly alter the structure of the protein. Variable sequon 
occupancy can give rise to glycoforms: this term essentially describes this structural 
diversity, which is a result of cell specific biosynthesis, and leads to functional diversity 
[Devasahayam, 2007]. 
Potential N-glycosylation sites can be identified by the presence of the Asn-Xxx-Ser/Thr 
sequon in peptide sequence databases; however it is very difficult to determine which of 
these sites are occupied. Structural analysis by X-ray crystallography can provide direct 
and unambiguous evidence for the occupancy of a glycosylation site; on the contrary, 
evidence from X-ray crystallography for the unoccupancy of a site is more ambiguous 
because the absence of the glycan is only one reason for the absence of resolved electron 
density [Petrescu et al., 2004].  
Comparative analysis of the properties of the protein around glycosylation sites can be 
helpful in identifying important glycosylation features. It has been shown that N-
glycosylation sequon occupancy is modulated by local aminoacid sequence: there is a 
marked preference for hydrophobic aminoacids at either side of the glycosylation site, 
with an increased probability of finding small hydrophobic amino acids at position +1 
and larger hydrophobic amino acids at position +3, whereas there is an increase in the 
probability of finding aromatic residues immediately before a glycosylation site. There is a 
significant above average occurrence of aromatic and Ser/Thr residues and a significantly 
below average occurrence of basic residues within 5 Å of a glycosylation site; there is also 
a large preference for Thr, as opposed to Ser, in position +2, due to a different affinity for 
the recruitment of the OST. In addition, the Asn-GlcNAc linkage only adopts one 
significant populated conformation: glycosylation, in fact, reduces the overall 
conformational freedom of the side chain and of the protein backbone (see paragraph 
2.2). Analysis of the secondary structures found around glycosylated Asn residues 
revealed that occupied glycosylation sites can occur on all forms of secondary structure, 
with a bias in favor of turns and bends (~27% and 17,5% respectively): the lowest 
incidence of glycosylation sites is on helices, with 10,5% incidence. The majority of sites 
are found in convex or flat regions of the surface; there is also a large number of 
glycosylation sites located on the edge of a groove, with the glycan filling partially or 
totally the depression. Finally about 10% of the glycans are situated in deep, narrow 
recesses in the protein surface: the positions of glycosylation sites may have evolved to act 
as landmarks for ending or starting regions of regular secondary structure.   
As well as stabilizing a particular local fold, glycans may play a role in organizing the 
folding process by promoting changes in backbone conformation of the folding 
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intermediates. Given the hydrophilic nature of monosaccharides, one might have 
expected to be there fewer occupied glycosylation sites with lower accessibilities and more 
with higher: the small number of potential sites with a very high accessibility is consistent 
with the idea that protein-glycan contacts are functionally significant and have been 
selected for during evolution [Petrescu et al., 2004].  
 
 
2.3.1 N-GLYCOSYLATION AND PROTEIN QUALITY CONTROL 
 
N-glycosylation plays a more general role early in the life of proteins, which is in the 
quality control of protein folding: the rough ER (rER) is not only the site of synthesis of 
secretory and membrane proteins but also of initial steps of protein N-glycosylation, and 
provides an environment promoting protein folding. Thus, the rER is also the main 
organelle in which the quality control of protein folding takes place. Both, the 
carbohydrate biosynthetic process and the resulting oligosaccharide are evolutionary 
conserved from yeast to mammals. 
The α1,2-linked outermost glucose residue is removed from the oligosaccharide, probably 
immediately after its transfer to the polypeptide, by oligosaccharyltransferase (Figure 2.2 
A). The reaction is catalyzed by glucosidase I, which is a neutral processing α1,2-
exoglucosidase of the glycosyl hydrolase family 63 with a type II membrane protein 
topology: removal of the outermost glucose residue by glucosidase I prevents further 
interaction of the oligosaccharide with the OGT. The two inner α1,3-linked glucose 
residues are subsequently removed by glucosidase II: this neutral processing α1,3-
exoglucosidase belongs to the glycosyl hydrolase family 31 and is a luminal glycoprotein 
composed of two subunits, a catalytic α subunit and a regulatory β subunit.  
In general terms, di-glucosylated oligosaccharides generated by glucosidase I appear to 
represent a glyco-code promoting protein N-glycosylation, by influencing the 
oligosaccharyltransferase-mediated reaction, whereas mono-glucosylated oligosaccharides 
represent a glyco-code promoting protein folding through the calnexin/calreticulin cycle 
(Figure 2.2 B). 
Like many chaperones present in the rER that shelter glycoproteins to prevent their 
aggregation and assist them in folding, the calnexin/calreticulin (CNX/CRT) cycle 
provides an environment for productive protein folding [Caramelo and Parodi, 2008]. 
Calnexin and calreticulin are highly related legume lectins with calnexin being a type I 
membrane protein and calreticulin being a soluble luminal ER protein: both are retained 
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in the ER through specific localization signals at their C-termini and have been found to 
form complexes with ERp57, a thiol-disulfide oxidoreductase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: A) Schematic representation of the sequential glucose trimming by glucosidases I and 
II; B) The calnexin/calreticulin cycle. 
 
 
The carbohydrate-binding specificity of calnexin and calreticulin appears to be identical: 
they both require the innermost α1,3-linked glucose residue present on the branch A of 
the oligosaccaride. Regardless, the first trimming reaction by glucosidase II resulting in 
the Glc1Man9GlcNAc2 oligosaccharide permits entry of the glycoprotein in the 
CNX/CRT cycle: the ensuing lectin-carbohydrate interaction acts in a chaperone-like 
fashion by sequestering the mono-glucosylated glycoproteins. Exit from the CNX/CRT 
cycle requires glucosidase II as well, which removes the innermost glucose residue: the 
fate of de-glycosylated glycoproteins after their exit from the CNX/CRT cycle strongly 
depends on their conformation. The folding sensor UDP-glucose:glycoprotein 
glycosyltransferase (UGGT) scans the structure of the polypeptide for exposed non-
native determinants: proteins with a native conformation can exit the ER, while if 
misfolded domains are detected then UGGT adds a glucose residue to the terminal 
mannose of branch A, thus returning the immature polypeptide to the CNX/CRT 
chaperone system, for another cycle [Herbert et al., 2005]. UGGT is a soluble luminal 
glycoprotein, which is present throughout the smooth and rER and concentrated in the 
pre-Golgi intermediates, and acts in a two-fold manner: first as a folding sensor and 
 
 
B 
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second as a glycosyltransferase [Trombetta and Parodi, 2003]. It can bind to non-native 
conformers most probably through interaction with exposed hydrophobic amino acid 
patches; this is followed by the re-glucosylation reaction and re-entry in the CNX/CRT 
cycle. However glycosylation by UGGT is transient, since the glucose residue will be 
removed by glucosidase II for exit from the CNX/CRT. For the majority of 
glycoproteins expressed in mammalian cells deletion of UGGT does not affect 
maturation, since most of them acquire native structure in a single round of association 
with calnexin and calreticulin.  
Re-glycosylation by UGGT occurs most efficiently when all nine mannoses are present 
and is less efficient for glycoproteins with Man8GlcNAc2 and Man7GlcNAc2 
oligosaccharides: some mannose trimming will occur between repeated CNX/CRT cycles, 
which may affect subsequent processing by UGGT and glucosidase II. The importance of 
mannosidase activities in the ER and their role in delaying and eventually preventing re-
entry of not correctly folded glycoproteins in the CNX/CRT cycle, has only recently been 
elucidated: both the folding state of a glycoprotein and the extent to which mannose 
residues have been removed seem to be important factors for the ER-Associated 
Degradation (ERAD) of not correctly folded glycoproteins. The substrate for ER 
mannosidase I is the Man9GlcNAc2 oligosaccharide, generated by the combined action of 
glucosidase I and II: mannosidase I cleaves a single α1,2 mannose residue to yield the 
Man8GlcNAc2. Additional mannose trimming yields Man7GlcNAc2 oligosaccharides, due 
to the removal of a mannose residue of the C branch: the irreversible cleavages of B and 
C branches serve as “Man timer”, while trimming of an additional α1,2-linked mannose 
residue to yield Man6GlcNAc2 sends the glycoprotein to ERAD. To further complicate 
the situation also an ER mannosidase II exists in mammalian cells: it also trims the 
Man9GlcNAc2 oligosaccharide, but more excessively to a Man5GlcNAc2 oligosaccharide, 
negatively affecting the rate of re-glucosylation by UGGT required for re-entry in the 
CNX/CRT cycle [Avezov et al., 2008]. Proteins that are fully defective for folding are 
ratined in the ER and targeteted to the ERAD pathway.   
An additional α-mannosidase I–like protein that lacks enzyme activity is also a resident of 
the ER: it is called EDEM (ER Degradation-Enhancing α-Mannosidase I–like protein) 
and it has an important role in the recognition of misfolded glycoproteins, thereby 
targeting them for ER degradation. Overexpression of EDEM resulted in accelerated 
release of misfolded glycoproteins from the CNX/CRT cycle and their subsequent 
degradation. EDEM binds selectively to not correctly folded glycoproteins: after exit 
from the CNX/CRT cycle, ER mannosidase I processes the oligosaccharides on not 
correctly folded glycoproteins to Man8GlcNAc2, which in turn is converted by EDEM to 
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Man7GlcNAc2 to provide the oligosaccharide for interaction with OS-9. The latter, a 
glycoprotein that contains a conserved mannose 6-phosphate receptor homology domain, 
selectively binds to non-native conformers of glycoproteins and routes them in the 
ERAD pathway through athe Hrd1/Hrd3 ubiquitin ligase complex. Various mechanisms, 
which involve distinct ubiquitin-ligase complexes, have been proposed to function in the 
management of ERAD substrates depending whether the misfolded protein is luminal 
(ERAD-L), cytosolic (ERAD-C) or intramembrane (ERAD-M) [Denic et al., 2006]. A 
glycoprotein that fails to be correctly folded during the Man trimming in the ER is 
retrogradely translocated in the cytosol through the protein-conducting channel, 
ubiquitinated by ubiquitin ligases, deglycosykated by peptide:N-glycanase (PNGase) and 
finally subjected to proteasomal degradation [Suzuki and Lennarz, 2003]. Among ERAD-
linked ubiquitin ligases it has been identified the sugar-recognizing Skp1-Cullin1-F-box 
(SCF) protein complex, in which the lectin activity is carried by the F-box protein (Figure 
2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: The role of glycan processing in regulating access to the lectin chaperone system or 
targeting for ERAD. 
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PNGase is a cytosolic enzyme that cleaves the β-aspartyl-glucosamine bond and removes 
the carbohydrate moieties from the misfolded glycoproteins, thereby facilitating 
proteasomal degradation: the carbohydrate moieties are bulky and therefore postulated to 
preclude proteasomal degradation of ubiquitinated substrates, since the active sites for 
proteolysis are within a narrow channel of the proteasome. In conclusion it is the 
trimming of carbohydrates and the elongation of polyubiquitin chains that target the 
protein to degradation [Kato and Kamiya, 2007]. 
The targeting of folding-defective polypeptides into the cytosol and proteasome-mediated 
destruction is crucial for mantenance of cell homeostasis: diverse proteins may not fold 
correctly because of disease-causing mutations and will be retained in the ER because of 
the quality control. Misfolded glycoproteins in addition can form self-aggregates or 
interact with proteins in addition to chaperones: since most disorders caused by protein 
misfolding are chronic diseases, ultrastructural changes may be observed only late 
[Moremen and Molinari, 2006].  
 
 
2.4 O-GLYCOSYLATION 
 
O-linked glycans often have lower mass thn N-linked structures, but can be more 
abundant and heterogeneous. In O-linked glycosylation the glycan is attached to the 
serine/threonine side chain, but unlike N-glycosylation, no consensus sequence exists. 
Linkages in which the sugar is attached to an aminoacid containing a hydroxyl group 
occur in great variety of proteins: every aminoacid with a hydroxyl functional group (Ser, 
Thr, Tyr, Hyp [hydroxyproline], Hyl [Hydroxylysine]) has been implicated. Through 
databases of O-glycosylated protein and statistical analysis on the sequences around target 
sites, preferential motifs for O-glycosylation have been identified leading to the 
development of algorithms for O-glycosylation prediction [Christlet and Veluraja, 2001]. 
Several O-glycosylation prediction softwares are available on the Internet, such as 
NetOGlyc 3.1 prediction server, which produces neural network predictions of ‘mucin-
type’ O-glycosylation sites in mammalian proteins [Julienus et al., 2005]. 
The O-glycosylation process produces an immense multiplicity of chemical structure: 
each monosaccharide has three or four attachment sites for linkeage of other sugar 
residues and can form glycosydic linkage in an α or β configuration, allowing glycan 
structures to form branches. 
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2.4.1 ‘MUCIN-TYPE’ O-GLYCOSYLATION 
 
O-glycosylation usually starts with an N-acetylgalactosamine (GalNAc) linked to Ser/Thr: 
this linkage has been considered a hallmark of mucin glycoproteins, which form part of 
the epithelial secretions in, for example, the gut, cervix and lungs. However a wide variety 
of glycoproteins contain this linkage [Hanisch et al., 2001]. At least nine GalNAc-
transferases exist: these enzymes work in concert in a hierarchical manner to form the 
clustered Ser/Thr-linked oligosaccharides that frequently occur in the ‘mucin-type’ 
glycoproteins. They are generally homologous to each other and although they act on 
characteristic peptide regions, no specific consensus sequence has been identified, mainly 
due to the multiplicity of the GalNAc-transferases [Clausen and Bennett 1996]. 
The O-GalNAc-α-Ser/Thr linkage is found in clusters of residues with a β-turn near 
proline and at a distance from charged aminoacids: in addition in vitro studies suggest that 
Thr is favoured over Ser for O-glycosylation [Elhammer et al., 1993]. This modification 
generally occurs in the cis-Golgi: however the multiplicity of enzymes composing this 
family makes it possible that some act also in a pre-Golgi or ER compartment 
[Hirschberg et al., 1998]. 
The biosynthesis of ‘mucin-type’ O-glycans can be divided into 3 stages. In the first stage 
nucleotide sugars are synthesized in the cytoplasm; in the second stage they are 
transported into the ER or the Golgi. In the third stage specific glycosyltransferases 
attach the sugars to a protein or to a glycan in the ER or Golgi. Monosaccharides used for 
the biosynthesis of nucleotide sugars derive from dietary sources and salvage pathways. 
Glucose and fructose are the major carbon sources in humans from which all other 
monosaccharides can be synthesized: series of phosphorylation, epimerization and 
acetylation reactions convert them into various high-energy nucleotide sugar donors, 
whose biosynthesis takes place in the cytosol. As the nucleotide sugars are synthesized in 
the cytosol they must be translocated into the lumen of the ER and/or Golgi: since they 
cannot cross the membrane lipid bilayer, specific transport mechanisms are responsible 
for their translocation. Two transport mechanisms can be distinguished: the first 
mechanism is the entrance of mannose and glucose through binding to the lipid carrier 
dolichol phosphate (Dol-P). The second transport mechanism exploits specific nucleotide 
sugar transporters (NSTs): these NSTs are antiporters in which nucleotide sugar entry 
into the ER and Golgi is coupled to equimolar exit of the corresponding nucleoside 
monophosphate from the lumen [Hirschberg et al., 1998]. After that a glycosyltransferase 
will transfer the monosaccharide to a glycan by cleaving off the nucleotide part: the 
nucleoside diphosphates are converted to dianionic nucleoside monophosphates, used for 
Chapter 2 – Protein glycosylation 
 36 
the antiporter, and inorganic phosphate by a nucleoside diphosphatase. Nucleoside di- 
and monophosphates can inhibit the nucleotide sugar transport process and the activity 
of glycosyltransferases.  
The activity of glycosyltransferases can be influenced by different factors. It is known, for 
example, that for optimal action some of the glycosyltransferases require divalent cations, 
such as Mn2+ or Mg2+. Furthermore, it was recently discovered that human core 1 β3-
galactosyltransferase (core 1 β3-Gal-T), which is involved in the formation of ‘mucin-
type’ O-glycans, requires a molecular chaperone for its functioning: this molecular 
chaperone is called Cosmc (core 1 β3-Gal-T-specific molecular chaperone) and is an ER-
localized type II transmembrane protein. A third factor that might influence 
glycosyltransferase activity is the structure of the protein substrate. However, how 
proteins are recognized by glycosyltransferases remains largely unknown.  
Finally, glycosyltransferase activity can be dependent on heterocomplex formation: 
glycosyltransferases involved in the linkage of monosaccharides to the protein backbone 
and those involved in the core processing of ‘mucin-type’ O-glycans are specific and not 
involved in other classes of glycoconjugates, whereas most glycosyltransferases involved 
in the elongation, branching, and termination of glycans are not specific for one 
glycoconjugate class. Given the sequential and competing nature of glycosyltransferases, 
the precise localization of these enzymes within the Golgi is of great importance: 
glycosyltransferases are arranged in an assembly line in the Golgi, whereas early-acting 
transferases are localized in the cis-Golgi, intermediate-acting transferases in the medial-
Golgi, and terminating transferases in the trans-Golgi [Opat et al., 2001].  
In general, O-linked glycans have been found to function in protein structure and stability, 
immunity, receptor-mediated signaling, modulation of enzyme activity and signaling 
molecules, protein interactions, expression and processing.  
Since O-glycosylation is a post-folding event, only Ser and Thr residues that are exposed 
on the protein surface will be glycosylated. Just like N-glycans, O-glycans can influence 
protein structure: the glycan can break the α-helicity of peptides; can have a role in the 
tertiary protein structure and in aggregation. Subsequently, O-linked glycans maintain 
protein stability, heat resistance, hydrophilicity, and protease resistance by steric hindrance 
[Wopereis et al., 2006]; another important function of O-linked sugars is to mediate 
immunologic recognition, such as recognition of glycopeptides by the MHC complex or 
by antibodies. Also the effects of O-linked glycosylation on the bioactivity of many 
signaling molecules, particularly hormones and cytokines, and a relatively small number of 
enzymes, have been described.  
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Many other O-linked glycosylation modification can occur: among them, GlcNAc-β-
Ser/Thr represents an increasingly important linkage, that is widely dispersed among 
eukaryote, from protozoa to higher mammals. It is distinctive since it can be found in 
nuclear and cytoskeletal proteins and indeed represents the first reported example of 
glycosylation found outside of the secretory channels [Hart, 1997]. 
 
 
2.4.2 O-β-GlcNAcYLATION 
 
The discovery of O-linked-β-N-acetylglucosamine (O-GlcNAc) more than 20 years ago 
disproved the long-held dogma that protein glycosylation is restricted to the luminal 
compartments of the secretory machinery and to the cell surface [Torres and Hart, 1984]. 
Thus far, O-GlcNAcylation has been documented in all metazoans, including 
Caenorhabditis elegans, insects, and plants. Even though O-GlcNAcylation is very abundant 
and widespread on most of the cell’s regulatory proteins, progress in understanding its 
roles in the cell has been slow, since it is generally undetected by commonly used 
analytical protein methods. In fact addition of the sugar does not generally affect 
migration of the glycopeptide in gel electrophoresis or in isoelectric focusing; second, the 
sugar modification is rapidly hydrolyzed by cellular hexosaminidases upon cellular damage 
or during protein isolation. Third, O-GlcNAc is labile by conventional mass 
spectrometric methods and it is lost at the source under conditions typically used in 
electrospray mass spectrometry.  
Subcellular fractionation of rat liver indicated that O-GlcNAcylated proteins are present 
in the cytoplasm and virtually in all subcellular organelles: many cytosolic enzymes, 
including kinases, glycolytic enzymes, cytoskeleton regulatory proteins, and cytoskeleton 
proteins themselves are modified. These same studies showed that the nucleoplasm, 
nuclear envelope and chromatin fractions are particularly enriched in O-GlcNAcylated 
proteins [Holt and Hart, 1986]; however the highest concentration of O-GlcNAcylated 
proteins occurs in the nuclear pore complex. Here glycoportiens are not required for the 
assembly of the nuclear envelope, for assembly of the major structures af the pore, or  for 
formation of the transport channel, but rather are essential for recognition of the nuclear 
localization signals and transport [Holt et al., 1987]. Moreover, several transcription 
factors are O-GlcNAcylated, with the modification being involved in nuclear transport, 
DNA binding, assembly into multimeric complexes or regulation of phosphorilation 
[Jackson and Tjian, 1988]; in addition to transcription factors, the largest subunit of RNA 
polymerase II is also multiply O-GlcNAcylated on its C-terminal domain (CTD). It has 
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been shown that during transcription initiation the CTD is O-GlcNAcylated and 
dephosphorylated, whereas upon transcriptional elongation it is deglycosylated and 
phopshotylated: this suggests a role for glycosylation in the assembly of the pre-initiation 
complex; subsequent to initiation, the O-GlcNAc moieties are removed and multiple 
phosphorylation allows elongation to occur. Histones, as well, are O-GlcNAcylated in vivo  
and O-GlcNAcylation changes during mitosis [Sakabe et al., 2010].  
O-GlcNAc could act as a protective signal against proteasomal degradation, both by 
modifying target substrates in PEST sequences (Pro-Glu-Ser-Thr sequences, known to 
mediate protein degradation), and by reversibly inhibiting the proteasome itself, through 
the O-GlcNAcylation of the 19S subunit [Guinez et al, 2008]:  this mechanism couples 
proteasomes to the general metabolic state of the cell, since it allows the organism to 
respond to its metabolic needs by controlling the availability of aminoacids and regulatory 
proteins. In fact O-GlcNAcylation is an end point of the hexosamine biosynthetic 
pathway, which culminates in the production of UDP-N-acetylglucosamine (UDP-
GlcNAc), the high-energy donor substrate for the O-GlcNAc transferase (OGT): virtually 
all metabolic pathways influence the cellular concentrations of UDP-GlcNAc: depending 
upon the cell type, as much as 2% to 5% of glucose is metabolized via the hexosamine 
biosynthetic pathway. Because the biosynthesis of UDP-GlcNAc is affected and regulated 
by nearly every metabolic pathway in the cell and because OGT-catalyzed O-
GlcNAcylation is sensitive to insulin, to nutrients, and to cellular stress, it has been 
proposed that O-GlcNAcylation serves primarily to modulate cellular signalling and 
transcription regulatory pathways in response to nutrients and stress (Figure 2.4). O-
GlcNAcylation of a large number of proteins in fact rapidly increases when cells are 
exposed to stress, including heat, high salt, heavy metals, UV light, hypoxia, and others: 
increased O-GlcNAcylation mediates stress tolerance through the upregulation of 
chaperones and heat shock proteins, both by increasing their expression and decreasing 
their turnover. 
 
 
2.4.3 ENZYMES INVOLVED IN O-GlcNAc CYCLING 
 
While Ser and Thr phosphorylation is determined by the action of over 300 different 
genetically encoded kinases, each with its own peptide selectivity  [Manning et al., 2002], 
O-β-GlcNAc is regulated only by two enzymes: a glycosylatransferase and a 
glucosaminidase.  
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Uridine diphospho-N-acetylglucosamine:peptide β-N-acetylglucosaminyltransferase 
(OGT) is comprised of two subunits with molecular weights of 110 kDa (α-subunit) and 
one of 78 kDa (β-subunit). OGT is present in all cells, but it is most aboundant in the 
glucose-sensing cells of the pancreas and in the brain. Although there is no absolute 
consensus sequence, approximately one-half of the known O-GlcNAc sites contain a 
PVS (Pro-Val-Ser) motif, similar to that recognized by proline-directed kinases; in 
addition, many of the known O-GlcNAc sites have high PEST scores, PEST being a 
sequence that is associated with rapid degradation when phosphorylated. OGT is a 
bifunctional protein with a catalytic C-terminal domain, which apparently evolved from 
the glycogen phosphorylase superfamily, and an N-terminal protein-protein interaction 
domain constituted by several tetratricopeptide repeats (TPRs) [Iyer and Hart, 2003]: its 
activity is sensitive to the concentration of the donor substrate, UDP-GlcNAc. OGT 
interacts with histone deacetylase complexes by binding to the corepressor mSin3A: the 
latter acts as a scaffold for the HDAC subunits and directly binds transcription factors, 
suggesting a direct between histone deacetylation and chromatin remodeling in the 
repression of transcription. OGT activity, recruited on transcriptionally inactive regions 
via mSin3A, might trigger the disassembly of the activation complex, shifting the 
equilibrium of the gene expression from an active to a repressive state [Yang et al., 2002].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: The O-GlcNAc code. 
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O-GlcNAc-specific β-N-acetylglucosaminidase (O-GlcNAcase) is a nucleocytoplasmic, 
neutral enzyme, composed of one 54 kDa-subunit (α subunit) and one 51 kDa-subunit (β 
subunit), which removes O-GlcNAc from peptide substrates glycosylated by OGT: like 
OGT, O-GlcNAcase is highly conserved and is expressed at the highest levels in pancreas, 
brain, and thymus. O-GlcNAcase is also a bifunctional protein with both a catalytic 
glycosydase domain at the N-terminus and an histone acetyltransferase (HAT) domain at 
the C-terminus: HAT domain allows the interaction of O-GlcNAcase with the 
transcription machinery, linking low-density O-GlcNAcylated proteins to transcription 
active regions. However within the nucleus and particularly at sites of transcription, the 
two O-GlcNAc cycling enzymes are often found within the same complex. 
 
 
2.4.4 ‘YIN-YANG’ MODEL 
 
Recent studies have shown that the modulation of cellular pathways and functions by O-
GlcNAcylation involves a very extensive cross talk with the pathways and mechanisms 
that are also regulated by protein phosphorylation signaling cascades: the system is not 
binary, with an ‘on’ and ‘off’ state for each signalling molecule; rather, the combination of 
modifications, differentially regulated, creates enormous molecular diversity. This cross-
talk has been defined as the ‘YinYang’ model [Hart et al., 1995]. 
Many proteins displayed reciprocal occupancy at the same Ser or Thr residue under 
different conditions, such as at sites on the c-Myc oncogene protein, estrogen receptor β, 
some sites on RNA polymerase II. However, a majority of transcription factors, such as 
p53 and FOXO1, displayed reciprocal occupancy of the two modifications at proximal 
sites on the polypeptide, but not at the same residue. Competition between O-
GlcNAcylation and phosphoryation for occupancy of Ser and Thr sites occurs by several 
distinct mechanisms. First, studies with synthetic O-GlcNAc peptides have suggested that 
addition of an O-GlcNAc moiety induces a β-turn conformation, while addition of a 
phosphate tends to open up the peptide conformation. In addition O-GlcNAcylation and 
phosphorylation dynamically modify the enzymes controlling each other’s cycling on 
polypeptides [Hart, 2011]. 
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2.5 GLYCOSYLATION AND DISEASES 
 
Alterations in any step of the N- and O-glycosylation process can be involved in the 
aetiology of many human congenital diseases, collectively referred to as congenital 
disorders of glycosylation (CDG). Moreover, O-GlcNAcylation dysregulation contributes 
to the aetiology of important human diseases, particularly diabetes and neurological 
disorders (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1:  Pathologies associated with aberrant O-GlcNAcylation. 
 
Given O-GlcNAc’s role as a nutrient sensor and its extensive cross talk with 
phosphorylation, it is not surprising that the protein modification plays fundamental roles 
in chronic diseases, particularly diabetes, neurodegeneration, cardiovascular disease, and 
cancer. In addition, many viruses that infect eukaryotic cells have key regulatory proteins 
that are also modified, presumably by the host O-GlcNAc cycling enzymes. It has long 
been postulated that the hexosamine biosynthetic pathway played a role in the etiology of 
diabetes and glucose toxicity. There are numerous genetic and other studies in insulin-
sensitive tissues, such as those of muscle, liver, and fat, that strongly support a direct 
involvement of O-GlcNAcylation and the hexosamine biosynthetic pathway in insulin 
resistance. Hyper-O-GlcNAcylation not only alters phosphorylation-mediated signalling 
cascades, but also alters the regulation of transcription [Slawson et al., 2010]. 
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2.5.1 CONGENITAL DISORDERS OF GLYCOSYATION 
 
Any step of the N-glycosylation process can be involved in the have crucial roles in the 
onset of congenital disorders of glycosylation (CDG). CDG form a group of autosomal 
recessive metabolic disorders caused by defects in the biosynthesis of protein-linked 
glycans. The primary defect of these disorders is not necessarily localized in one of the 
glycan-specific transferases, but can likewise be found in the biosynthesis of nucleotide 
sugars, their transport to the ER and Golgi, and in Golgi trafficking: defects can lead to a 
severe autosomal recessive multisystem syndrome with neurologic involvement, whereas 
some defects do not produce a clinical phenotype.  
It is becoming increasingly evident that also defects in the O-glycosylation process can be 
ascribed to CDG. The clinical variations among the different errors of O-glycan 
metabolism can be enormous: as O-glycans are involved in numerous processes, it is 
inevitable that defects in O-glycan biosynthesis might lead to severe abnormalities for 
cellular functioning.  
The majority of patients with ‘classical CDG’ have a defect in N-glycan biosynthesis. 
They have common symptoms such as muscle hypotonia, central nervous system 
abnormalities, growth delay, feeding problems, coagulation defects and liver disease, and 
frequently show specific signs such as abnormal fat distribution and inverted nipples, 
which help with the early clinical diagnosis. In contrast, patients with O-glycosylation 
disorders commonly have involvement of only one organ or one organ system and do not 
have the general symptoms that are suggestive for an inborn error of metabolism. Most of 
the disorders of O-glycan biosynthesis seem to have very specific tissue expression, 
whereas N-glycans are expressed ubiquitously. Another remarkable difference between N- 
and O-glycan deficiencies is that N-glycan deficiencies generally have recessive inheritance, 
whereas in some of the O-glycan biosynthesis diseases inheritance is autosomal dominant. 
Patients with combined defects in protein N- and O-glycosylation often have a phenotype 
that is a mixture of the features of inborn errors in combination with congenital 
malformations [Wopereis et al., 2006]. 
 
 
2.5.2 GLYCOSYATION AND DIABETES 
 
O-GlcNAc transferase (OGT) uses the donor sugar UDP-GlcNAc: concentrations of 
UDP-GlcNAc, which is also the end product of the hexosamine biosinthetic pathway, are 
highly sensitive to ambient glucose levels (see paragraph 2.4.2). Increased flux through the 
hexosamine pathway under hyperglycemic conditions leads to elevated levels of O-
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GlcNAc modified proteins in skeletal muscle and in pancreatic beta cells. In the case of 
muscle cells, reduced insulin receptor substrate (IRS) –1 and –2 signaling are associated 
with their increased O-GlcNAc modification and decreased phosphorylation, causing 
attenuated insulin stimulated signaling. For example, hyperglycemic conditions increase 
O-GlcNAcylation of the transcription factor Sp1, which correlates with increased Sp1-
dependent TGFβ1 expression. Thus, altered O-GlcNAc levels under hyperglycemic 
conditions appear to perturb normal signaling events required for insulin-mediated 
homeostasis [Vosseller et al., 2001]. 
Hyperglycemia is associated with insulin resistance, although the underlying molecular 
mechanisms for this effect are still largely unknown. O-GlcNAc has a key role in the 
regulation of insulin signalling and as a mediator of glucose toxicity [Buse, 2006]: 
increasing O-GlcNAcylation in adipocytes or muscle blocks insulin signalling at several 
points. Elevated O-GlcNAcylation on insulin receptor substrate seems to reduce its 
interaction with phosphatidylinositol-3-OH kinase, thus blocking insulin signalling at an 
early stage. Moreover many aspects of glucose toxicity require its metabolism into 
glucosamine, which, in turn, elevates UDP-GlcNAc and increases O-GlcNAcylation. 
Hyperglycemia, hyperlipidamia and hyperinsulinemia all result in abnormal increases in O-
GlcNAcylation, which disturb the normal dynamic balance between O-GlcNAcylation 
and O-phosphorylation that controls signalling, transcription and other cellular functions. 
 
 
2.5.3 NEURODEGENERATIVE DISEASES 
 
O-GlcNAcylation plays an important role in both normal brain functions and the etiology 
of neurodegeneration, contributing to transcriptional regulation, neuronal communication 
and neurodegenerative disease. O-GlcNAcylation was recently shown to play a role in 
neuronal plasticity, regulating the number of axonal filopodia and the ability of axons to 
elaborate branches: over-expression of O-GlcNAcase promoted the formation of axon 
branches, even In the context of injury and regeneration [Francisco et al., 2009]. However 
unlike diabetes, in these cases higher O-GlcNAcylation appears to prevent disease, and 
impaired glucose metabolism, with the resulting lower O-GlcNAcylation in brain, leads to 
hyperphosphorylation which contributes to neuronal cell death.  
Approximately, one quarter of the neuronal proteins are O-GlcNAcylated, involving 
important processes such as transcription, neuronal signaling and synaptic plasticity. 
These proteins can be transcription factors, such as cAMP-responsive element binding 
protein (CREB), coactivators and corepressors, as the steroid receptor coactivator-1 
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(SRC1), and cytoskeletal proteins such as neurofilaments, microtubule-associated proteins 
and the β-amyloid precursor protein (APP). An intriguing interplay between O-GlcNAc 
glycosylation and phosphorylation has been observed in cerebellar neurons, wherein 
activation of certain kinase pathways reduces O-GlcNAc levels on cytoskeleton-
associated proteins. Finally, recent studies suggest that O-GlcNAc is dynamically 
regulated by excitatory stimulation of the brain in vivo [Rexach et al., 2008]. 
There is considerable indirect evidence that O-GlcNAc may play a role in 
neurodegenerative disorders. Interestingly, OGT maps to the X-linked Parkinson 
dystonia locus and O-GlcNAcase maps to the Alzheimer’s disease locus on chromosome 
10 [Wells et al., 2003]. 
Evidence has been mounting connecting defects in glucose metabolism in the brain with 
neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s Disease 
[Dias and Hart, 2007]. Virtually all proteins involved in AD can be both O-GlcNAcylated 
and phosphorylated. Neuron glucose metabolism declines with age and this decline is 
more marked in AD neurons, concomitant with reduced O-GlcNAc [Liu et al., 2009]. 
One normal function of O-GlcNAc seems to be the prevention of excessive 
phosphorylation at sites at which this would be deleterious. 
Tau protein is required for microtubule polymerization and stability in neurons, and is the 
major component of neurofibrillary tangles associated with the disease: in normal brain it 
is extensively O-GlcNAcylated at more than 12 sites and is hyperphosphorylated in AD 
brain, which in turn causes it to aggregate into the paired helical filaments that constitute 
the visible neurofibrillary tangles characteristic of the disease [Liu et al., 2004].  
The amyloid-β precursor protein (APP) is O-GlcNAcylated and its cytoplasmic tail is  
phosphorylated, which is known to affect its proteolytic processing. Abnormal proteolysis 
of APP gives rise to the toxic β1–42 peptide fragment, which forms amyloid plaques that 
are found in neurons in Alzheimer’s disease. Neurofilaments are hypo-O-Glc-NAcylated 
in neurons in a rat model of amyotrophic lateral sclerosis. O-GlcNAcylation of the 
clathrin assembly proteins AP-3 and AP-180 declines in Alzheimer’s disease, suggesting 
that reduced O-GlcNAcylation contributes to the loss of synaptic vesicle recycling [Hart 
et al., 2007]. 
Finally, O-GlcNAc glycosylation has been demonstrated to inhibit the proteasome, thus 
providing a mechanism to couple ubiquitin-mediated protein degradation to the general 
metabolic state of the cell: blocking the removal of O-GlcNAc from the proteasome leads 
to increased protein ubiquitination and possibly neuronal apoptosis. Proteasomal 
dysfunction and ubiquitinated inclusion bodies are found in the diseased tissue of 
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individuals with Amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s 
disease and Alzheimer’s disease [Ciechanocer and Brundin, 2003]. 
 
 
2.5.4 GLYCOSYATION AND CANCER 
 
In every organism all cellular functions can be distinguished in two general typologies: in 
fact there are cells endowed with ‘social’ functions, such as cell-cell interactions and cell-
matrix interactions, in contrast to cells with ‘housekeeping’ functions, such as gene 
expression and cell replication. These different functions are regulated by glycosylation 
and phosphorylarion, respectively: tumor cell motility and metastasis are complex 
processes which result mainly by the alteration of ‘social’ functions. Glycans esposed on 
tumour cells can behave both as adhesion molecules, that can alter cell motility, and as 
transmembrane signaling molecules, able to carry signals across the plasma membrane 
and regulate tumour growth. Glycosylation also affects the trafficking of cell adhesion 
molecules that are important for metastasis: for example, O-GlcNAcylation of β-catenin 
not only regulates its nuclear localization and transcriptional activity, but also blocks its 
association with E-cadherin, a cell adhesion molecule critical to epithelial cell adhesion. 
Aberrant glycosylation observed in tumour cells can become a good method for diagnosis 
and prognosis of tumour progression: in fact there is a clear correlation between aberrant 
glycosylation in primary tumours and their invasiveness [Hakomori, 1996]. 
As noted above many oncogenes or tumour suppressors play a direct role in regulating 
transcription, and nearly all such proteins are modified by glycosylation such as c-Myc, 
retinoblastoma (Rb), β-catenin, estrogen receptors, and others. Given the extensive cross-
talk between O-GlcNAcylation and phosphorylation, and the known roles of 
phosphorylation in mechanisms underlying cancer, it is not surprising that O-
GlcNAcylation is also involved in cancer aetiology [Kamemura and Hart, 2003]: O-
GlcNAc modification adds another level of regulation, which could allow for exquisite 
control of cell regulatory mechanisms. Disruptions of either of these post-translational 
modifications may interfere with critical control mechanisms, leading to the transformed 
phenotype [Comer and Hart, 2000]. For example, the c-myc oncogene is glycosylated in 
its transactivation domain at Thr-58, which is also the mutational hotspot found in a large 
percentage of Burkitt’s lymphomas in patients; interestingly, this glycosylation site is also 
an important phosphorylation site that regulates c-myc transcriptional activity. The 
tumour suppressor, p53, which is the most commonly mutated gene in a wide range of 
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human cancers, is also O-GlcNAc-modified: there is preliminary evidence that the O-
GlcNAc on p53 regulates its binding to DNA.   
 
 
2.6 THERAPEUTIC GLYCOPROTEINS  
 
Glycosylation patterns of recombinant proteins are relevant for the immunogenicity, the 
pharmacological activity, pharmacokinetic profile, solubility and stability of the protein. 
Processing of oligosaccharides is specified by the processing enzymes present in the cell. 
Hence the glycoform populations for a glycoprotein are both species and cell specific. 
The importance of therapeutic proteins has grown rapidly since the emergence of the 
biotechnology industry: currently 64 products have been approved by regulatory agencies, 
with some 500 product candidates in clinical and preclinical development. Of these, 
approximately 70% are glycoproteins [Walsh, 2005]. Therapeutic proteins were initially 
derived from human sources; however, concerns over product purity and consistency, the 
potential for viral contamination and the emergence of genetic engineering tools has 
shifted their production into recombinant expression systems, such as mammalian cell 
lines, bacteria, yeast and insect cells. However these expression systems vary widely, with 
regard to their ability to incorporate the post-translational modifications found on native 
human proteins: because many proteins of therapeutic importance require N-
glycosylation for biological activity, expression systems with N-glycosylation capability 
have become essential for therapeutic glycoprotein production. In fact not-correct 
glycoforms can adversely affect pharmacokinetic properties of the recombinant 
glycoprotein and raise immunogenicity and safety concerns: thus, the therapeutic use of 
glycoproteins derived from expression systems that do not perform human glycosylation 
could lead to rapid clearance, complement activation, and enhanced immunogenicity by 
targeting to antigen-presenting cells [Sethuraman and Stadheim, 2006]. 
Glycans contribute significantly to the hydrodynamic volume and charge of glycoproteins. 
In particular, the content of sialic acid contributes to the net negative charge, and 
improves the pharmacokinetics of glycoproteins such as erythropoietin (EPO) 
[Macdougall, 2002]. Although glycosylation can improve plasma half-life, the presence of 
certain carbohydrate moieties can trigger lectin-mediated clearance, thereby reducing 
plasma half-life: in fact lectins are differentially expressed in tissues so that therapeutic 
proteins with distinct glycans can be developed for cell- and tissue-specific targeting.  An 
expression system that allows for control over the glycosylation of therapeutic proteins 
has, until recently, been unavailable. Through the customization of glycan profiles, such 
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as that recently demonstrated in glycoengineered yeast, it is now possible to systematically 
probe for glycosylation-dependent therapeutic effects: increased availability of 
glycoengineered expression systems will enable a greater understanding of structure-
function relationships among glycoforms, which should lead to the development of novel 
therapeutics [Sethuraman and Stadheim, 2006]. 
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3.  AIM OF THE STUDY 
 
Cells of a multicelluar organism are structurally and functionally heterogeneous: the 
diversity of cell phenotype is due to differential transcription programs precisely regulated 
by specific nuclear factors and induced upon differentiation. As regards neuronal cells, it 
thus becomes of crucial interest to understand the molecular mechanisms regulating 
central nervous system-specific genes expression in the nervous system and their 
repression in other tissues. Gene expression can be controlled by positively acting cell-
type-specific or tissue-specific transcription factors; however also negative-acting silencers 
participate in preventing the expression of neuronal genes in non-neuronal cell types or in 
inappropriate neuronal subtypes.  
As previously described, the original role proposed for REST was of transcription factor 
responsible for restricting or limiting neuronal gene expression to the nervous system, by 
silencing the expression of the regulated genes in non-neuronal cells. However, since its 
discovery as a negative regulator of neuronal differentiation, REST has been implicated in 
several processes such as maintenance of embryonic stem cell (ESC) pluripotency, self-
renewal and regulation of mitotic fidelity in non-neuronal cells.  
REST gene is expressed in both embryonic stem cells (ESCs) and neural stem cells 
(NSCs). In ES cells, consistent levels of nuclear REST occur and the REST-corepressor 
complex strongly represses target genes. As the ES cells start to differentiate into NSCs, 
most of the REST is degraded through the proteasomal pathway whereas lower amounts 
of REST mRNA are transcribed by the gene transcriptional machinery. It has been 
hypothesized that in NSCs, as the levels of REST decrease, the REST-corepressor 
complex may still occupy the RE-1 sequence in target genes but represses them less 
substantially than in ES cells, causing them to be poised for transcription. However, the 
expression of multiple neuronal differentiation genes requires both the absence of REST 
function and the presence of other promoter/enhancer-specific positive activators. 
Therefore, as the NSCs exit the cell cycle and differentiate into mature neurons, REST 
gene transcription is decreased. In the absence of active REST transcription, REST 
protein levels diminish, resulting in the expression of numerous genes. Taken together, 
these findings suggest that at ESC level, are already present and finely regulated cellular 
processes that modulate post-traslational mechanisms that may contribute to modify its 
stability as well as its interaction with other transcription factors or with regulatory 
sequences of the target genes.  
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The aim of this study was to investigate if one the most relevant processes involved in the 
post-traslational regulation of proteins: N-linked glycosylation, may contribute to REST 
folding, stability and interaction with other proteins and DNA.  
REST gene encodes a 116-kDa protein that contains a DNA-binding domain, composed 
of eight zinc-fingers, an N-terminal repressor domain and one zinc finger at the C-
terminal repressor domain [Ballas and Mandel, 2005]. By acting as an evolving molecular 
platform to which diverse factors may be recruited, REST promotes dynamic 
modifications of DNA, histones, nucleosomes and higher-order chromatin codes and 
helps maintaining genomic stability. Although REST molecular weight, calculated on 
aminoacid sequence, is about 116 kDa it was found to migrate on SDS-PAGE as 
different molecular weight protein (see Table 1.1); thus, suggesting the possible presence 
of post-translational modifications of the protein backbone. However, up to now, only 
the presence of O-glycan chains has been evidenced; thus indicating the contribution of 
O-lined glycosylation to REST functions [Lee et al., 2000] whereas is unknown ay 
contribution of N-linked glycosylation. 
Although the most common way to generate protein diversity is, of course, alteration of 
the order and composition of their constituent amino acids, additional diversity is 
generated by covalent modification of amino acids by post-translational modifications: 
while only 20 amino acids are used in protein synthesis, as many as 140 different amino 
acids are found in proteins due to covalent post-translational modification [Vosseller et 
al., 2001]. Glycosylation, that is the covalent attachment of one or more carbohydrates 
that occurs during or after the process of protein synthesis, causing stable and long-term 
changes of the native protein, is another relevant and only partially known event. 
Although the number of different types of glycosidic bond is continuously increasing, N- 
and O-linked glycans still remain the most abundant. The process of glycosylation 
involves about 1% of human genes [Lowe and Marth, 2003]; furthermore, according to 
estimates based on the SwissProt database, more than one half of all proteins are 
glycosylated [Apweiler et al., 1999]. Glycosylation may affect many protein activities: it has 
been shown to facilitate folding kinetics and to affect the biophysical properties of 
proteins. The observation that N-glycosylation starts during protein synthesis, when the 
glycan is added to the still unfolded protein, indicates that it may assist in obtaining the 
correct fold [Roth et al., 2010]. On the contrary O-linked glycans often have lower mass 
than N-linked structures but they can be more abundant and heterogeneous. O-linked 
glycans have been found to function in protein structure and stability, immunity, 
receptor-mediated signaling, modulation of enzyme activity and signaling molecules, 
protein interactions, expression and processing. Moreover the discovery of O-linked-β-N-
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acetylglucosamine (O-GlcNAc) more than 20 years ago disproved the long-held dogma 
that protein glycosylation is restricted to the luminal compartments of the secretory 
machinery and to the cell surface: several transcription factors are O-GlcNAcylated, with 
the modification being involved in nuclear transport, DNA binding, assembly into 
multimeric complexes or regulation of phosphorylation [Torres and Hart, 1984]. 
Alterations in any step of the N- and O-glycosylation process can be involved in the 
aetiology of many human disorders, such as congenital diseases, diabetes, degeneration 
and cancer [Wopereis et al., 2006].  
REST, as well, has been found to be involved in the establishment of the same diseases. 
Particularly, it has been proposed that it may have a double role in the pathogenesis of 
cancer, since it can behave both as an oncogene and an oncosuppressor.  
Moving from these observations, we hypothesized the presence of glycan chains in the 
aminoacid backbone of REST and investigated the presence of glycosylation chains in the 
aminoacidic backbone of the REST protein with the aim to relate this post-translational 
modifications to its repressor transcriptional activity. Particularly, our goal is to identify 
and characterize the N-lined glycosylation pattern of REST to understand any correlation 
between alteration of glycosylation and protein misfunction and to translate this 
correlation in any pathological conditions where such post-traslational events could be 
modified. 
First of all, using different deglycosylating enzymes we investigated the composition of 
the glycan chains present in REST. Thereafter, we ascertained their composition through 
mass spectrometry analysis and confirmed the presence of complex glycan chains in 
REST by expressing the protein in vitro in suitable prokaryotic and eukaryotic systems.  
The second step was to identify REST aminoacid residues bearing N-linked glycan chains. 
Using suitable post-translational prediction software, we identified aminoacids that could 
be target of N-linked glycosylation events; afterwards, these aminoacids were mutated by 
site-directed mutagenesis. We generated nine plasmids bearing REST mutant forms where 
a sequential removal of glycan chains was obtained.  The plasmids were expressed in cell 
lines of embryonic or neuronal origin and we analyzed molecular weight and ability of 
REST mutated forms to bind to the RE-1 DNA consensus sequence by gel-shift analysis. 
Finally, we investigated the contribution of glycan chains in the repressor transcriptional 
activity by employing gene reporter assays.  
In conclusion, the present study aims to contribute to a more accurate comprehension of 
the post-traslational processes modulating REST activity and useful for a more detailed 
knowledge of crucial biological events like neurogenesis and oncogenesis. Moreover, 
considering the important role of protein glycosylation and of transcription factors in the 
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aetiology of many disease states, any further knowledge in this field may become relevant 
for future pharmacological therapies. 
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4.  MATERIALS AND METHODS 
 
4.1 MATERIALS 
 
Cell culture media, fetal bovine serum (FBS) and horse serum (HS) were from Lonza 
(Basel, Switzerland). EXGEN 500 Transfection Reagent was from Fermentas (Hanover, 
MD, USA). The rabbit polyclonal antibody anti-REST purchased from Upstate-Millipore 
(Darmstadt, Germany) is raised against residues 801-1097 of the protein; the polyclonal 
rabbit anti-REST antibody from Bethyl Laboratories (Montgomery, USA) is raised against 
residues 1050-1097. Monoclonal anti-FLAG M5 antibody was from Sigma-Aldrich (St. 
Louis, MO, USA). The peroxidase-conjugated secondary antibodies goat anti-mouse IgG 
and goat anti-rabbit IgG were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, 
USA).  
Glycoprotein Deglycosylation kit was purchased from Calbiochem-Merck (Darmstadt, 
Germany), while Native Protein Degycosylation kit from Sigma-Aldrich (St. Louis, MO, 
USA). Rabbit Reticulocyte Lysate (TnT T7 Coupled Reticulocyte Lysate System) and 
Escherichia coli lysates (S30 T7 High-Yield Protein Expression System) were purchased 
from Promega (Madison, WI, USA).  
Restriction enzymes were obtained from Roche (Mannheim, Germany) or Fermentas 
(Hanover, MD, USA). NE-PER Extraction Reagent kit and LightShift Chemiluminescent 
Electrophoretic Mobility Shift Assay kit were from Pierce (Rockford - IL, USA). Biotin-
labeled oligonucleotides were from Sigma-Aldrich (St. Louis, MO, USA). 
Recombinant human IGF-I, Reporter Lysis Buffer, Bright-Glo Luciferase Assay System 
and Beta-Glo Assay System were all purchased from Promega.  
All other reagents were of analytical grade or of the highest purity available, purchased 
from Sigma-Aldrich (St. Louis, MO, USA). 
 
 
4.2 CELL COLTURE 
 
SH-SY5Y cells were obtained from the European Collection of Cell Cultures (Salisbury, 
UK) and routinely grown as monolayers in MEM and Ham’s F12 (1:1) medium, 
supplemented with 15% (v/v) fetal bovine serum (FBS), L-glutamine (2mM), 1% non-
essential amino acids and 1× antibiotic-antimycotic solution in a humidified environment 
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containing 5% CO2 and 95% air. Cells were grown in 75-cm2 flasks, detached with a cell 
scraper and viability was determined using trypan blue staining. Cells were analysed in an 
inverted phase contrast microscope (Eclipse TS100; Nikon). 
HEK293 cells were obtained from European Collection of Cell Cultures (Salisbury, UK) 
and routinely grown as monolayers in EMEM (EBSS) supplemented of 2mM glutamine, 
1% non essential amino acids, 10% FBS (v/v) and 1× antibiotic-antimycotic solution in a 
humidified environment containing 5% CO2 and 95% air. Cells were grown in 75-cm2 
flasks, or alternatively were plated in 100mm dishes, and detached with a 10% 
Trypsin/EDTA solution. Cells, at 50–60% confluence, were transiently transfected with 
pCMV-Tag2B+REST plasmid, which contains REST coding sequence fused to FLAG 
epitope,  or with plasmids encoding for different REST mutants (10µg/dish) using the 
EXGEN 500 Transfection Reagent (Fermentas, Hanover, MD, USA). 72h post-
transfection, cells were collected and nuclear and cytoplasmic proteins were extracted.  
Rat pheochromocytoma PC-12 cells (European Collection of Cell Culture) were grown in 
RPMI 1640 medium supplemented with 10% heat-inactivated (55°C, 30 min) horse  
serum, 5% FBS and 1x antibiotic-antimycotic solution. Cells were cultured at 37°C in a 
humidified atmosphere of 5% CO2.  
For REST over-expression and gene reporter experiments, PC-12 cells were seeded in 
100mm dishes and in 24-well plates, respectively, coated with Collagen type IV from 
human placenta 0,1 mg/mL (Sigma-Aldrich), transiently transfected through EXGEN 
500 Transfection Reagent and harvested 72 or 48h later, respectively, with a 10% 
Trypsin/EDTA solution. 
 
 
4.3 WESTERN BLOTTING 
 
Nuclear and cytoplasmic protein fractions were obtained using the commercial NE-PER 
Extraction Reagent kit (Pierce): lysis and resuspension buffers contained a mixture of 
protease inhibitors composed of 0,5 mg/mL Benzamidine, 2 µg/mL Aprotinin, 2 µg/mL 
Leupeptin and 0,75 mM phenylmethlysulfonyl fluoride.  
Cells were scraped off in 10mL cold PBS, pelleted and resuspended in 200mL of CER I 
buffer: after 10min incubation on ice, 11mL of CER II buffer were added and the 
suspension was vortexed, incubated on ice for 1min and then separated by centrifugation 
at 12000g for 5min. To obtain the nuclear extract, the cell pellet was resuspended in 
100mL of NER buffer and incubated on ice for 40min: the soluble proteins in the lysate 
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were separated by centrifugation at 12000g for 10min at 4 C. Protein samples were then 
kept at – 80°C.  
Protein concentration was determined using the Lowry method [Lowry et al., 1951]. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blotting were performed according to standard procedures: proteins from the nuclear 
extract (70 µg for SH-SY5Y and HEK-293 cells and 100 µg for PC-12 cells) were 
separated by 7% SDS-PAGE and transferred onto a Hubond-ECL nitrocellulose 
membrane (GE Healthcare). As a molecular weight standard we used the Magic Marker 
XP (Invitrogen). 
For detection of REST protein, the blots were blocked with 3% non-fat milk in TBS 
(10mM Tris-HCl, pH8, containing 150mM NaCl) for 1,5h at room temperature and then 
incubated overnight at 4°C with the rabbit polyclonal IgG directed against REST, used at 
a dilution of 1:2000 (Upstate) or 1:2500 (Bethyl Lab). Alternatively, the recombinant 
FLAG-REST protein was detected by blocking the membrane with 5% non-fat milk in 
TBS (10mM Tris-HCl, pH8, containing 150mM NaCl) plus 0,1% Tween 20 for 1,5h at 
room temperature, and then incubating the membrane 5% milk in TBS-T 0,1% with the 
anti-FLAG M5 (Sigma) mouse monoclonal IgG directed against FLAG, a 1:2000 dilution 
was used, for 1,5h at room temperature. The membranes were incubated with peroxidase-
conjugated secondary antibodies at a dilution of 1:8000, for 1,5h at room temperature. 
Detection of immunoreactive bands was done by the enhanced chemiluminescent 
method (Immobilon Western Chemiluminescent HRP Substrate – Millipore) and a 
FUJILAS3000 acquisition camera. 
 
 
4.4 ENZYMATIC DEGLYCOSYLATION 
 
In order to characterize glycan chains present in REST we performed an enzymatic 
removal of O-linked oligosaccarides using Glycoprotein Deglycosylation kit, following 
manufacturer instruction for the non-denaturing protocol (Calbiochem). Briefly, reaction 
mixtures contained 0,5 µL each of several enzymes, alone or in combination (PNGase F, 
α2-3,6,8,9-neuraminidase, Endo-α-N-acetylgalactosaminidase, β1,4-galactosidase and β-N-
acetylglucosaminidase), 100 µg of proteins, and 5X reaction buffer (250mM sodium 
phosphate buffer, pH 7.0): the mixtures were incubated at 37°C for 3 days and then 
analyzed using western blotting. 
N-linked glycan chains removal was performed using the Native Protein Degycosylation 
kit from Sigma-Aldrich (St. Louis, MO, USA): 100 µg of proteins were incubated with 1 
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µL each of different enzymes (Endoglycosidase F1, Endoglycosidase F2 and Endoglycosidase F3) 
and 10 µL of 5X reaction buffer (250mM sodium phosphate buffer, pH 5.5)and then 
incubated at 37°C for 1 hour. Subsequently they have been analyzed by western blotting. 
 
 
4.5 CELL-FREE PROTEIN SYNTHESIS 
 
The cell-free translation system employed were an extract from rabbit reticulocytes or 
Escherichia coli: they use DNA as a template, from which RNA is transcribed and 
subsequently translated without any purification.  
 
 
4.5.1 ESCHERICHIA COLI PROTEIN EXPRESSION  
 
The S30 T7 High-Yield Protein Expression System (Promega) is an E. coli extract-based 
cell-free protein synthesis system: it contains all the macromolecular components (70S 
ribosomes, tRNAs, aminoacyl-tRNA synthetases, initiation, elongation and termination 
factors) required for transcription and translation of exogenous DNA. To ensure efficient 
translation, each extract must be supplemented with amino acids, energy sources (ATP, 
GTP), energy regenerating systems (phosphoenol pyruvate and pyruvate kinase), and co-
factors like Mg2+and K+. 
This E. coli-based protein expression system uses the bacteriophage T7 RNA polymerase 
and a T7 promoter, and permits high-level expression of REST recombinant protein: the 
T7 RNA polymerase is typically supplied by inducing a recombinant T7 polymerase gene 
contained on a lambda lysogen in the host strain. During transcription the 5' end of the 
RNA becomes available for ribosomal binding and undergoes translation, while its 3' end 
is still being transcribed: this early binding of ribosomes to the RNA maintains transcript 
stability and promotes efficient translation. 
2 µg of template plasmid DNA (pSP72+REST) was incubated with 20 mL S30 premix 
plus and 18 mL T7 S30 extract: the tube was then vortexed and centrifuged for 5 seconds, 
to force the reaction mixture to the bottom of the tube. In vitro transcription and 
translation occurred for 60 min at 37°C with vigorous shaking: the reaction was stopped 
by incubating the tube for 5 min on ice and samples have been denatured for 2 min at 
95°C, just before loading the sample for SDS-PAGE. 
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4.5.2 RETICULOCYTE LYSATE PROTEIN EXPRESSION  
 
Rabbit Reticulocyte Lysates (Promega) are a highly efficient in vitro eukaryotic protein 
synthesis system which combines the T7 prokaryotic phage RNA polymerase and 
promoter with eukaryotic extracts, in presence of energy regenerating systems such as 
creatine phosphate and creatine phosphokinase, to synthesize proteins from exogenous 
DNA templates. In vivo reticulocytes are highly specialized cells primarily responsible for 
the synthesis of hemoglobin, which represents more than 90% of the proteins that they 
produce. Reticulocytes are immature red cells which have already lost their nuclei: they 
have to be purified to remove contaminating cells, which could otherwise alter the 
translational properties of the extract, and then treated with micrococcal nuclease to 
destroy endogenous globin mRNA, thus reducing background translation to a minimum. 
Many factors affect translation efficiency of a specific mRNA in Rabbit Reticulocyte 
Lysates like, for example, the presence of certain nucleic acid sequence elements such as 
poly(A) tails, 5´-caps, 5´-untranslated regions and the sequence context, which can have 
profound effects on initiation fidelity and translation efficiency. In addition, Rabbit 
Reticulocyte Lysates may contain a variety of post-translational processing activities, 
including acetylation, isoprenylation, phosphorylation and glycosylation.  
The reaction was assembled in a 1,5 mL tube, by adding 25 µL of TnT Rabbit 
Reticulocyte Lysate, 2 µL of Reaction Buffer, 0,5 µL of each T7 RNA Polymerase 
Aminoacid mixture (-Met and -Leu), 1 µg of template DNA (pSP72+REST), 1 µL of T7 
RNA Polymerase and 1 µL of Ribonuclease Inhibitor: the mixture was resuspended and 
centrifuged briefly, then incubated at 30°C for 90 min.  
As a positive control of in vitro protein synthesis, a transcription/translation reaction of 
the firefly luciferase coupled to a luciferase activity assay was set: this is an excellent 
control for in vitro translation because only full-length luciferase is active. The luciferase 
synthesis was evaluated by measuring light intensity, which depends on the rate of 
catalysis of luciferin by synthetic luciferase, through a luminometer. Assembly of the 
control reaction mixture is similar to the one described above, except that the DNA 
template is a plasmid encoding firefly luciferase. 
 
 
4.6 IMMUNOPRECIPITATION 
 
FLAG peptide (N-DYKDDDDK-C) is a synthetic polypeptide which is absent from any 
natural peptide sequence: REST coding sequence has been previously cloned downstream 
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of the FLAG peptide coding sequence, so that FLAG could be used for purification and 
identification assays. With the aim of affinity-purifying REST from nuclear protein 
extracts we optimized an immunoprecipitation protocol, which exploits the binding 
affinity of the monoclonal anti-FLAG M2 IgG covalently attached to agarose beads. 
2 mg of nuclear protein extract, denatured at 95°C for 5 min, were incubated with 40 µL 
of FLAG M2 agarose resin, previously washed twice with 0,5 mL TBS (50mM TrisHCl, 
150mM NaCl, pH 7.4) and centrifuged at 12000g for 1 min at 4°C: the protein and resin 
were incubated over-night at 4°C on a roller shaker. The next day the resin was 
centrifuged and the supernatant kept as the wash fraction, then washed three more times 
with TBS: FLAG-REST was eluted in 50 µL of a 200 µg/mL FLAG peptide solution, 
incubated with vigorous shaking at 4°C for 30 min. After centrifugation, the supernatant 
containing purified FLAG-REST was immediately loaded for SDS-PAGE or stored at     
-80°C.  
 
 
4.7 MASS SPECTROMETRY ANALYSIS 
 
Mass spectrometry (MS) is an ideal method for protein mass determination: the two 
primary methods for ionization of proteins are electrospray ionization (ESI) and matrix-
assisted laser desorption/ionization (MALDI). In a MALDI source, proteins typically 
carry a charge state of +1 and since mass spectrometers measure the m/z ratio 
(mass/charge state), proteins typically appear with their mass plus the mass of a single 
hydrogen ion in a MALDI TOF spectrum.  
 
 
4.7.1 GLYCAN COMPOSITION ANALYSIS 
 
MS, with its low sample requirement and high sensitivity, has been the predominantly 
technique used in glycobiology for characterization and elucidation of glycan structures, 
since provides a complementary method to HPLC for the analysis of glycans.  However, 
the composition of native oligosaccharides is variable due to the presence of N-acetylated 
and acidic residues, and this variation affects ionization capabilities of the 
oligosaccharides, sometimes preventing them from being detected by MS. For this reason, 
derivatization of oligosaccharides by chemical means such as permethylation is often 
performed before MS analysis, because this chemical modification stabilizes the sialic acid 
residues in acidic oligosaccharides. Moreover, the addition of methyl groups to 
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oligosaccharides also enables them to become more uniformly ionized by reducing the 
variation of the chemical properties among the glycans, caused by the presence of highly 
polar –OH and –NH2 groups in the molecule; methylated glycans ionize more efficiently 
than their native counterparts, and due to their hydrophobic nature, are easily separated 
from salts and other impurities that may affect the MS analysis. Additionally, the 
fragmentation of methylated glycans is more predictable than that of their native 
counterparts, leading to accurate structural assignments when MS/MS analysis is 
performed [Dell et al. 1994; Kang et al. 2005].  
Purified nuclear protein extracts obtained from HEK-293 cells stably expressing 
recombinant FLAG-REST have been analyzed through MALDI/TOF mass spectrometry 
by the Glycotechnology Core Resource (University of California, UCSD): they were first 
denatured, to make linkages susceptible to enzymatic digestion, and then digested with 
pronase. The sample was treated with PNGase F to release the N-linked glycans, which 
were fractionated through a reversed-phase C18 column; subsequently oligosaccharides 
were permethylated and the modified glycan fractions have been characterized by 
MALDI/TOF mass spectrometry. The instrument used is the QSTAR XL qTOF Maldi-
Mass Spectrometer, a hybrid quadrapole time-of-flight mass spectrometer ideally suited 
for the analysis of all classes of glycoconjugates, including free glycans, glycopeptides and 
for protein identification and peptide sequencing.  
 
 
4.7.2 GLYCOSYLATION SITE MAPPING 
 
The incontrovertible identification of REST aminoacidic residues target of glycosylation 
can be obtained only through mass spectrometry: purified protein extracts have been 
analyzed through MS/MS by the Complex Carbohydrate Research Center (University of 
Georgia). To elucidate N-glycosylation target sites 18O-labeling method and LC-MS/MS 
were used.  
Purified REST extracts were reduced with 25mM DTT for 1h at 55°C and 
carboxyamidomethylated with 90mM iodoacetamide in the dark for 45min; the dried 
dialyzed sample was resuspended in 50mM ammonium bicarbonate and digested with 2,5 
µg of trypsin at 25°C for 20h. Following deactivation of trypsin at 100°C for 5min, the 
sample was then deglycosylated with 2 µg of PNGase F in 36 µL of 18O water and 2 µL of 
1M ammonium bicarbonate; labeled peptides were then analyzed by C18 capillary 
chromatography LC/MS. The mixture of peptides was resuspended with 200 µL of 
mobile phase A (0.1% formic acid in water) and the sample was loaded onto a nanospray 
Chapter 4 – Materials and methods 
 59 
tapered capillary column/emitter (360x75x15µm, PicoFrit, New Objective, Woburn, MA) 
self-packed with C18 reverse-phase resin (10.5cm, Waters, Milford, MA) in a Nitrogen 
pressure bomb for 10min at 1,000psi (~5µL load), and then separated via a 160min linear 
gradient of increasing mobile phase B at a flow rate of~500nL/min directly into the mass 
spectrometer. LC-MS/MS analysis was performed on a linear quadrupole ion trap LTQ 
Orbitrap Discoverer mass spectrometer (Thermo Scientific) equipped with a nanospray 
ion source: the resulting data were searched against the REST sequence using the 
TurboSequest algorithm (Proteome Discoverer 1.1, Thermo Scientific): the SEQUEST 
parameters were set to allow 30.0 ppm of precursor ion mass tolerance and 0.8 Da of 
fragment ion tolerance with monoisotopic mass. Tryptic peptides were allowed with up to 
two missed internal cleavage sites, and the differential modifications of 57.02146 Da, 
15.9949 Da and 2.98826 Da were allowed for alkylated cysteine, oxidation of methionines 
and 18O-labeled aspartic acid, respectively. 
 
 
4.8 PREDICTION OF GLYCOSYLATION TARGET SITES 
 
NetOGlyc 3.1 server, available via internet http://www.cbs.dtu.dk/services/NetOGlyc/, is a 
revised non-redundant database of glycoproteins with O-linked glycosylation sites, which 
produces neural network predictions of mucin type N-acetylagalactosamine (GalNAc) O-
glycosylation sites in mammalian proteins: the criteria for inclusion in that database are at 
least on experimentally verified O-glycosylation site. A method for predicting the location 
for mucin-type glycosylation sites was trained using a neural network approach. The best 
overall network used as input aminoacid composition, averaged surface accessibility 
predictions, together with substitution matrix profile encoding of the sequence; to 
improve prediction on isolated sites, networks were trained on isolated sites only. The 
final method combines predictions from the best overall network and the best isolated 
site network and this prediction method correctly predicted 76% of the glycosylated 
residues and 93% of the non-glycosylated residues.  
O-linked-β-N-acetylglucosamine (O-GlcNAc) does not display a definite consensus 
sequence: however the glycosylation motif is marked by the close vicinity of proline 
residues (positions -4,-3,-2), valines (-1,+2,+4,+5) and a downstream tract of serines 
(+1,+4,+7), though leucines and glutamines are disfavoured. Moving from these 
considerations the YinOYang server was generated 
(http://www.cbs.dtu.dk/services/YinOYang/): it is a good predictor for O-GlcNAc attachment 
sites in eukaryotic protein sequences, based on neural networks on 40 experimentally 
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determined O-GlcNAc acceptor sites. In a cross-validation 72,5% of the glycosylated sites 
and the 79,5% of the non-glycosylated sites were identified by the server. 
An N-glycosylation site predictor for human proteins, called NetNGlyc, is available at 
http://www.cbs.dtu.dk/services/NetNGlyc/: it examines the sequence context of Asn-Xaa-
Ser/Thr sequons using artificial neural networks. Artificial neural networks are trained on 
the surrounding sequence context, in an attempt to discriminate between acceptor and 
non-acceptor sequons: in a cross-validated performance, the networks could identify 86% 
of the glycosylated and 61% of the non-glycosylated sequons, with an overall accuracy of 
76%.  
 
 
4.9 SITE-DIRECTED MUTAGENESIS 
 
In vitro site-directed mutagenesis is an invaluable technique for characterizing the dynamic, 
complex relationships between protein structure and function. The QuikChange II XL 
Site-Directed Mutagenesis kit (Agilent Technologies) was used since it is specifically 
optimized for large constructs, allowing site-specific mutation of the double-stranded 
plasmid DNA in a three-step procedure, with high mutation efficiency and decreased 
potential for random mutations. It is performed using PfuUltra high-fidelity DNA 
polymerase for mutagenic primer-directed replication of both plasmid strands: the 
procedure utilizes a supercoiled double-stranded DNA vector, with an insert of interest, 
and two synthetic oligonucleotide primers, both containing the desired mutation. The 
oligonucleotide primers, each complementary to opposite strands of the vector, are 
extended during temperature cycling by PfuUltra DNA polymerase, without primer 
displacement; extension of the oligonucleotide primers generates a mutated plasmid 
containing staggered nicks. Following temperature cycling the product is treated with 
DpnI, an endonuclease specific for methylated and hemimethylated DNA used to digest 
the parental DNA template and to select for mutation-containing synthesized DNA: 
finally the nicked vector DNA incorporating the desired mutations is transformed into 
XL-10 Gold ultracompetent cells. 
REST mutant forms have been obtained starting from the wild-type form of REST, 
encoded by the plasmid vector pCMV-Tag2B+REST; concerning N-linked glycosylation, 
starting from the single mutant N59Q multiple mutants have been obtained, by mutating 
one predicted N-glycosylation each time and using the previous mutant plasmid as 
template.  
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4.9.1 MUTAGENIC PRIMER DESIGN 
 
The mutagenic oligonucleotide primers used for site-directed mutagenesis must be 
designed individually according to the desired mutation and to the following rules [Zheng 
et al., 2004]: 
 Both mutagenic primers must contain the desired mutation and anneal to the same 
sequence on opposite strands of the plasmid; 
 Primers should be between 25 and 45 bases in length, with a melting temperature 
≥ 78°C; 
 The desired mutation should be in the middle of the primer, with ~10-15 bases of 
correct sequence on both sides; 
 The primers should have a minimum GC content of 40% and should terminate in 
one or more C or G bases; 
 At the 3’ ending of each primer there should be at least 8 non-overlapping bases, 
while the primers must perfectly overlap at their 5’ end. 
To estimate the Tm of primers the following formula must be used: 
Tm = 81,5+0,4(%GC)-675/N-%mismatch, 
where N is the primer length in bases. 
Codons corresponding to serine (TCA) and threonine (ACA) have been converted to 
alanine (GCA) with a single nucleotide substitution, while codons corresponding to 
asparagine (AAT) have been converted to glutamine (CAA), with a double substitution. 
Table 4.1 summarizes the primers we designed and used for site-directed mutagenesis. 
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MUTANT 
NAME 
TARGET 
NUCLEOTIDE 
PRIMER SEQUENCE 
T618A a1852g                  5’-GCCTGCTCCCGCAGAGGCGGTTCAGAAGGGGCCCG-3’ 
        3’-GTCTACCCCGGACGAGGGCGTCTCCGCCAAGTCTT -5’ 
S971A t2911g 
           5’-GAAGAACCAGTTGCACCAATGCTTCCCCCTTCAGCAGTAG-3’ 
 3’-GTTGTCAACTTCTTGGTCAACGTGGTTACGAAGGGGGAAG-5’ 
N59Q A175c  t177a 
                                           5’-GGGGAAGTACAAGGCAGCTGCTGTGATTACCTGGTCGGTG-3’ 
3’-CCGTTTACACCGGAATTGACCCCTTCATGTTCCGTCGACG-5’ 
N83Q a247c  c249a 
                                             5’-GGGGATAACCAATTTTCAGATAGTGAAGAAGGAGAAGG-3’ 
  3’CCGTCTTGACTACGGCCAACCCCTATTGGTTAAAAGTC-5’ 
N417Q a1249c  t1251a 
                                    5’-TCCTACTTGTCCTCAAAAAACAATGGATGTCTCAAAAGTG-3’ 
    3’-GTTTAGATTCGTAGGATGAACAGGAGTTTTTTGTTACCTA-5’ 
N440Q a1318c  t1320a                                             5’-GACTTGCCTGATCAAATTACCAATGAAAAAACAGAAATAGAAC-3’ 
   3’-GGTTTTTTGCTCTCCGACTGAACGGACTAGTTTAATGGTTACT-5’ 
N482Q a1444c  t1446a 
                                         5’-AGCCTTCTAATCAAGTGTCAGTGATCCAGGTGACTACCAG-3’ 
  3’-CAGAGTTTTCTCTTTTTCGGAAGATTAGTTCACGTCACT-5’ 
N958Q a2872c  t2874a 
                                       5’-CACCCGAGAGCAACTCACTGGTATAAATTCAACAGTTGAAG-3’ 
     3’-CCTGTGACTAGTCTTGTGTTCTCTCGTTGAGTGACCATATT-5’ 
N1000Q a2998c  t3000a                                                  5’-ATGGCAGCACAAGAGTCTCAGGAAATTGATGAAGATGAAG-3’ 
   3’-CCGTAGTGGAGGACGATGTTACCGTCGTGTTCTCAGAGTC-5’ 
 
Table 4.1: List of primers used for site-directed mutagenesis. 
 
 
4.9.2 MUTAGENESIS REACTION 
 
To synthesize the mutant plasmid the reaction was assembled as follows: 
 
 VOLUME (µL) 
10x REACTION BUFFER 5 
template plasmid DNA 50 ng 
Primer FORWARD (125ng) 2 
Primer REVERSE (125ng) 2 
dNTP MIX 1 
Quik Solution 3 
PfuUltra DNA polymerase 1 
Nuclease-free water To a final volume of 50 µL  
 
Table 4.2: List of reaction components mixed for the mutant synthesis reaction. 
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Each site-directed mutagenesis reaction was run according to the protocol reported in 
Table 4.3 
 
Segment Cycles Temperature Time 
1 1 95°C 1 min 
95°C 50 sec 
62°C 50 sec 
 
2 
 
18 
   68°C 8.5 min 
3 1 68°C 7 min 
 
Table 4.3: Cycling parameters for the QuikChange II XL method. 
 
The PCR product obtained was digested with 1 µL of the DpnI restriction enzyme 
(10U/ µL), for 1h at 37°C; subsequently 2 µL of the DpnI-treated DNA were added to 45 
µL of ultracompetent cells, previously thawed on ice and incubated with 2 µL of β-
mercaptoethanol on ice for 10 minutes. The transformation reaction was incubated on ice 
for 30 min and heat-pulsed in 42°C water bath for 30 seconds: after that the reaction was 
incubated on ice for 2 minutes and then o,5 mL of pre-heated NZY+ broth (10 g/L 
casein hydrolysate, 5 g/L yeast extract, 5 g/L NaCl, pH 7.5, supplemented with 1M 
MgCl2, 1M MgSO4, 2M glucose) were added to the tube, leaving the transformation 
reaction at 37°C for 1 hour with gentle shaking (225-250 rpm). Finally, the transformation 
reaction was plated on agar plates containing Kanamicin for plasmid vector selection. 
 
 
4.10 ELECTROPHORETIC MOBILITY SHIFT ASSAY 
 
Electrophoretic mobility shift assays were performed using 15µg of nuclear protein 
extract obtained from HEK-293 cells or PC-12 cells transiently transfected with wild-type 
or different  mutant forms of REST. The probe was a 60-bp biotin end-labeled, duplex 
oligonucleotide containing the 21-bp RE-1 sequence upstream of the human µ-opioid 
receptor gene (hMOR):  
(sense, 
5’CTTGGTTGCGGTGGGGCCGGGGTCAGTACCATGGACAGCAGCCGGCGG
CTGGCGGGGAGCA-3’; 
complementary sequence, 
5’TCTCCCCGCCAGCCGCCGGCTGCTGTCCATGGTACTGACCCCGGCCCCACC
GCAACCAAG-3’) [Bedini et al., 2010].  
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DNA binding reactions were set up employing the LightShift Chemiluminescent 
Electrophoretic Mobility Shift Assay kit (Pierce), the nuclear protein extract and 62.5fmol 
of biotin-labeled oligonucleotide duplex. For competition assays, a 50 or 100-fold molar 
excess of unlabeled oligonucleotide duplex were used as competitors (the sequence is the 
same reported above) and added just before the biotin end-labeled probe. The reactions 
were performed in the standard binding buffer supplied (10mM Tris-HCl, 50mM KCl, 
1mM DTT, pH7.5) plus 5mM MgCl2 and 50ng/µL poly(dI-dC) non-specific competitor 
DNA and were incubated for 20min at room temperature. In supershift samples, 15µg of 
nuclear protein extract were pre-incubated at room temperature with 5 µg of anti-REST 
polyclonal antibody (Upstate) or anti-FLAG M5 monoclonal antibody (Sigma) for 30min 
at room temperature before adding the probe. The reaction mixture was loaded onto a 
5% non-denaturating polyacrylamide gel with 0.5× TBE buffer and electrophoresed for 
60min at 100V. The gel was transferred to a nylon membrane (Nytran; Schleicher & 
Schuell Italia) in 0.5× TBE at ~350mA for 60min. The transferred DNA was cross-linked 
(120mJ/cm2 for 1min at 254nm) using a UV cross-linker and the detection was 
performed by a chemiluminescent procedure as indicated by the manufacturer. 
 
 
4.11 REPORTER GENE ASSAY 
 
PC-12 cells were plated in in collagen IV (Sigma)-coated 24-well dishes  and at 50-60% 
confluence were transiently transfected with 1.4 µg/ well of hMOR promoter/luciferase 
reporter plasmid (pGL3+LNpMOR), 0.7 µg/well of the plasmid that encodes for wild-
type or mutant FLAG-REST (pCMV-Tag2B+REST) and 0.4 µg/well of the 
normalization plasmid pSV- Gal (Promega), using the EXGEN 500 Transfection 
Reagent (Fermentas, Hanover, MD, USA). Cells were cultured in serum-free medium for 
12 h, then exposed to 10nM IGF-I or left untreated for 24 h. Finally, cells were lysed in 
Reporter Lysis Buffer (Promega) and samples were collected. 
Luciferase and beta-galactosidase activities of cell lysates were measured with the Bright-
Glo Luciferase Assay System or Beta-Glo Assay System (Promega), according to the 
manufacturer’s instructions. 
The reporter plasmid is based on the pGL3 Basic vector system (Promega) containing the 
firefly luciferase reporter gene and was obtained as reported elsewhere [Bedini et al., 
2008].  
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5.  RESULTS 
 
5.1 ANALYSIS OF NATIVE REST PROTEIN 
 
Although the molecular weight calculated on the basis of REST aminoacidic sequence is 
about 116 kDa, western blotting analysis shows that this transcription factor has higher 
apparent molecular weights (see Table 1.1). The difference could be explained by post-
translational modifications of the protein. Although REST4 was found to be O-
glycosylated between residues 87 and 152 [Lee et al., 2000], full length REST could 
contain additional glycosylation sites. We observed that REST protein migrates on SDS-
PAGE with a specific pattern of bands, differing among various cell lines and between 
the nuclear and the cytosolic form of the protein.  
To study the endogenous form of REST we evaluated the expression of this transcription 
factor in the neuroblastoma cell line SH-SY5Y and in the embryonic cell line HEK-293: 
to recogne REST protein, two antibodies have been used, both raised against the C-
terminal region of the protein (see paragraph 4.3). 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.1.1: Western blotting analysis of endogenous REST expressed in neuroblasoma SH-
SY5Y cells, from A) nuclear and B) cytoplasmic extracts. Detection was carried out using two 
different commercial antibodies, raised against the C-terminal region of REST (Upstate and 
Bethyl). 
 
Nuclear protein extracts of neuroblastoma cells present at least three specific bands 
corresponding to REST, of apparent molecular weights of ~200, ~150 and ~120 kDa, 
consistent with different steps of post-translational modification of the protein backbone 
(Figure 5.1.1 A). On the contrary, cytoplasmic protein extracts migrate as two bands of 
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apparent molecular weight around 130-180 kDa (Figure 5.1.1 B). Native REST in 
embryonic HEK-293 cell nuclei migrates in SDS-PAGE with a specific pattern of 
apparent molecular weight of ~200, ~150 and ~120 kDa, as seen in neuroblastoma cells; 
cytoplasmic extracts, however, showed a double band of apparent molecular weight of 
~130-150 kDa (Figure 5.1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.2: Western blotting analysis of endogenous REST protein from nuclear and 
cytoplasmic extracts, expressed in embryonic HEK-293 cells. Detection was carried out using 
Upstate  anti-REST antibody. 
 
 
5.2 ENZYMATIC DEGLYCOSYLATION OF REST 
 
Moving from the observation that REST shows distinct patterns of bands in SDS-PAGE 
analysis, we started studying the composition of the glycan chains present in the protein: 
for this purpose we applied a strategy of enzymatic deglycosylation, using different 
combinations of enzymes capable of specifically remove the glucidic residues.  
We used N-glycosidase F (PNGase F), one of the most effective method of removing all N-
linked oligosaccharides from glycoproteins. Once released from the protein backbone, the 
oligosaccharide is left intact and therefore suitable for further analysis, while the 
asparagine residue from which the sugar was removed is deaminated to aspartic acid. The 
substrate of PNGase F is the glycosylated tripeptide Asn-X-Ser/Thr, but the presence of 
steric hindrance could inhibit enzyme activity (Figure 5.2.1) [Maley et al., 1989]. 
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Figure 5.2.1: PNGase F enzymatic cleavage site. R1 = polipeptide backbone, R2 = carbhydrate 
or hydrogen atom, R3 = hydrogen atom. 
 
Therefore, particular residues, due to their location in the native protein structure, are 
often resistant to the traditional deglycosylation with PNGase F: additional specific 
enzymes can be used for the removal of N-linked oligosaccharides from glycoproteins 
under native conditions.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 5.2.2: Schematic representation of the Endoglycosidases action; Endo F1, Endo F2 and Endo 
F3 specificity is indicated. 
 
Endoglycosidase F1, F2 and F3 are less sensitive to protein conformation than PNGase F 
and more suitable for deglycosylation of native proteins. In particular oligomannose and 
hybrid structures can be removed by Endoglycosidase F1, or Endo F1 (Figure 5.2.2 A), while 
biantennary and triantennary structures can be removed by Endoglycosidase F2 and F3 
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respectively, also known as Endo F2 and Endo F3 (Figure 5.2.2 B and C). These enzymes 
cleave the oligosaccharide between two N-acetylglucosamine residues in the 
diacetylchitobiose core thus generating a truncated sugar molecule with one N-
acetylglucosamine residue remaining on the asparagine. In addition, all complex 
oligosaccharides can be reduced to the trimannosylchitobiose core by treatment of the 
glycoproteins with neuraminidase, β-galactosidase and N-acetylglucosaminidase. 
There is no enzyme comparable to N-glycosidase F for removing intact O-linked sugars. 
The enzyme Endo-α-N-acetylgalactosaminidase (Endo-α) can remove the intact core structure 
intact without any modification of the serine or threonine residues, but any modification 
of the core structure will block the action of the enzyme (Figure 5.2.3): however external 
monosaccharides must be removed by a series of exoglycosidases until only the 
Galβ1,3GalNAc core remains attached to serine or threonine. 
 
 
 
 
 
Figure 5.2.3: Schematic representation of the Endo-α-N-acetylgalactosaminidase  cleavage site.  
 
The most common modification of the core structure that can block the action of Endo-
α is mono-, di-, or trisialylation: these residue can be easily removed by the action of α2-
3,6,8,9-neuraminidase, since this enzyme is efficient at cleaving the NeuNAcα2,8-NeuNAc 
bond. A less common, but widely distributed O-linked hexasaccharide structure, contains 
β1,4-linked galactose and β1,6-linked N-acetylglucosamine: complete removal of this O-
linked structures or its derivatives would require a β1,4-galactosidase and a β-N-
acetylglucosaminidase (Figure 5.2.4). 
 
 
 
 
 
 
 
Figure 5.2.4: Schematic representation of the enzymatic removal of O-linked glycan chains from 
the Gal-β-(1-3)-GalNAc core of glycosylation. 
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Western blotting analysis of nuclear protein extracts from SH-SY5Y cells showed that the 
treatment with PNGase F did not cause any alteration in the migration of the bands 
identified as REST, even in denaturing conditions (Figure 5.2.5 A), suggesting that if N-
glycan chains are present in the protein they can be buried in the protein core and 
unaccessible to the enzyme. The combination of all the enzymes necessary for O-
glycosylation removal (Endo-α + Galactosidase + Neuraminidase + β-N-acetylglucosaminidase), 
caused the appearance of one additional band in the sample called O-degly, whose apparent 
molecular weight is about 180 kDa (Figure 5.2.5 A) and which is much more evident in 
the non-denaturing protocol (see paragraph 4.4). Also treatment with Endo F1 caused the 
appearance of an additional band of an apparent molecular weight of about 180 kDa 
(Figure 5.2.5 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.5: Western blotting analysis of endogenous REST nuclear protein expressed in 
neuroblasoma SH-SY5Y cells, deglycosylated by: A) PNGase F and the combination of Endo-
α, neuraminidase, galactosidase and N-acetylglucosaminidase (O-degly); B) Endo F1, F2 or F3. 
 
To further understand the composition of the oligosaccharides we tested enzymatic 
deglycosylation abilities of the same set of enzymes both on endogenous REST expressed 
in HEK-293 cells and on the recombinant FLAG-REST protein, stably expressed in 
HEK-293 cells. To this aim recombinant REST has been cloned in a plasmid vector 
downstream of a sequence encoding for the FLAG peptide (N-DYKDDDDK-C), a 
synthetic polypeptide which is absent from any natural peptide sequence. First the over-
expression of FLAG-REST has been verified through western blotting analysis: in Figure 
5.2.6 is shown that transfection of the recombinant protein causes an increment in the 
intensity of the band corresponding to the fully glycosylated form of REST. Subsequently, 
nuclear protein extracts have been subjected to enzymatic deglycosylation: as can be seen 
in Figure 5.2.7, PNGase F, Endo F2 and Endo-α alone cause no variations in band 
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migration, since the three bands corresponding to REST apparent molecular weights of 
approximately 200, 150 and 120 kDa did notchange with respect to the Negative control 
sample. On the contrary, treatment with the combination of Endo-α + Galactosidase or 
with all the enzymes necessary for O-glycosylation removal, also called O-degly, caused the 
appearance of one additional band, whose apparent molecular weight is about 180 kDa, 
and the increment in intensity of the band of 120 kDa, as highlighted by the red circles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.6: Western blotting analysis of nuclear protein extracts of the recombinant FLAG-
REST protein expressed in HEK-293 cells. Detection was carried out using: A) Upstate  anti-
REST antibody; B)anti-FLAG M5 antibody. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.7: Western blotting analysis of the recombinant FLAG-REST after enzymatic 
deglycosylation with PNGase F, Endo-α, the combination of Endo- α and β−galactosidase, the 
combination of Endo-α, neuraminidase, β -galactosidase and N-acetylglucosaminidase (O-degly), Endo F1, 
Endo F1 and the combination of Endo F1, Endo F2 and Endo F3. 
 
Similarly, treatment with Endoglycosidase F1 caused the reduction of apparent molecular 
weight of the fully glycosylated form of REST and the appearance of an additional of 
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about 180 kDa. The same results were obtained also with the endogenous REST 
expressed in HEK-293 cells (data not shown).  
Starting from these observations we hypothesized the presence of both N- and O-linked 
oligosaccharides in REST protein, but N-linked glycan chains seem to be buried in the 
protein structure, since PNGase F could not remove them. 
 
 
5.3 CELL-FREE IN VITRO REST SYNTHESIS 
 
In vitro synthesis of proteins in cell-free extracts is a useful tool in molecular biology and 
has a variety of applications, including the rapid identification of gene products, protein 
folding studies, protein interactions, protein structure and post-translational modifications 
analysis. The most frequently used cell-free translation systems consist of extracts from 
rabbit reticulocytes or Escherichia coli: both of them use DNA as a template, from which 
RNA is transcribed and subsequently translated without any purification.  
The S30 T7 High-Yield Protein Expression System (Promega) is an E. coli extract-based 
cell-free protein synthesis system: it permits transcription and translation of DNA 
sequences cloned in plasmids downstream a T7 promoter, by providing an extract that 
contains a bacteriophage T7 RNA polymerase and all necessary components for 
translation, thus allowing the production of high levels of recombinant proteins. Large 
differences in the level of gene expression could be obtained due to the size of the 
protein, the gene of interest and the context in which the gene resides, especially relative 
to the ribosome binding site (RBS). RBS is generally located approximately seven bases 
upstream of the AUG start codon; in addition, many eukaryotic genes contain sequences 
within the protein-coding region that can function as ribosomal-binding sites when they 
precede a methionine codon. 
Rabbit reticulocyte lysates (Promega) is a highly efficient in vitro eukaryotic protein 
synthesis system: it typically combines a prokaryotic phage RNA polymerase and 
promoter (T7 in our case) with eukaryotic extracts to synthesize proteins from exogenous 
DNA templates. For the highest protein yield and the best initiation fidelity, the DNA 
template must have a Shine-Dalgarno RBS upstream of the initiation codon. Rabbit 
Reticulocyte Lysate may contain a variety of post-translational processing activities, 
including acetylation, isoprenylation, phosphorylation and glycosylation.  
As shown in Figure 5.3.1 synthetic REST protein produced in the E.coli cell-free system 
migrates in SDS-PAGE with an apparent molecular weight of about 120 kDa, 
comparable to the expected non-glycosylated form of endogenous REST. On the 
Chapter 5 - Results 
 72 
contrary, the synthetic protein produced by the Rabbit Reticulocyte Lysate system shows 
an apparent molecular weight of about 220 kDa, similar to the fully glycosylated form of 
endogenous REST, expressed in SH-SY5Y cells and loaded in the SDS-PAGE as a 
positive control. 
These results confirm our first hypothesis that REST is modified by the addition of 
complex glycan chains in the protein backbone, since only eukaryotic extracts were able 
to synthesize a protein with the exact folding and post-translational modifications, 
showing  the proper apparent molecular weight on western blotting analysis.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.1 Western blotting analysis of the cell-free in vitro synthesized REST protein, 
produced in E. coli or in Rabbit Reticulocyte Lysate systems and compared to the endoguenous 
REST extracted from SH-SY5Y cells. E.coli REST migrates with an apparent molecular weight of 
~120 kDa, comparable to the expected non-glycosylated form of endogenous REST; Rabbit 
Reticulocyte Lysate REST shows an apparent molecular weight of ~220 kDa, similar to the fully 
glycosylated endogenous REST. 
 
 
 
5.4 MASS SPECTROMETRY ANALYSIS 
 
To further confirm REST glycosylation we subjected recombinant REST protein extracts, 
obtained from HEK-293 cells stably transfected with the FLAG-REST plasmid construct, 
to mass spectrometry analysis, in order to depict the glycan chains in terms of 
oligosaccharide composition and linkage analysis. For this purpose, the protein extracts 
had to be purified by immuno-affinity, using an agarose resin conjugated with anti-FLAG 
antibody capable to bind FLAG-REST and purify it from any other protein present in the 
nuclear extract. Figure 5.4.1 shows that immunoprecipitated FLAG-REST (IP REST) is 
enriched in the fully glycosylated form of the protein, if compared with the non-
Fully glycosylated 
REST 
Not-glycosylated 
REST 
Ma
rke
r
E. 
Co
li
RE
ST
Ra
bb
it
Re
tic
ulo
cyt
e
RE
ST
SH
-
SY
5Y
220
100
120
kDa
80
 
Chapter 5 - Results 
 73 
immunoprecipitated extract (input), while the non-glycosylated protein is removed by 
washing steps (see wash fraction).   
 
 
 
 
  
 
 
 
 
 
Figure 5.4.1: Western blotting analysis of the immunoprecipitated recombinant FLAG-REST 
protein stably expressed in HEK-293 cells, using anti-REST antibody.  
 
 
5.4.1 GLYCAN COMPOSITION ANALYSIS 
 
Protein extracts so far purified were analyzed through MALDI/TOF mass spectrometry 
by the Glycotechnology Core Resource (University of California, UCSD). Purified protein 
extracts were first denatured to make linkages susceptible to enzymatic digestion and the 
glycoprotein sample was then digested with pronase into peptides. The sample was treated 
with PNGase F to release the N-linked glycans, which were fractionated by passing the 
sample through a reversed-phase C18 column, which enables a significant reduction in 
sample complexity prior to mass spectrometry analysis without loss of important 
components. Subsequently permethylation of oligosaccharides was used to improve their 
signals by mass spectrometric analysis (see paragraph 4.7): released N-glycan fractions 
were characterized by MALDI/TOF mass spectrometry. REST has been shown to have a 
very complex mixture of glycans but the ion intensities of some species are at noise level; 
however, there are some dominant glycans, as showed in Figure 5.4.2, having higher peak 
intensities, which confirm the presence of N-linked glycan chains composed of N-
acetylgalactosamine, galactose and mannose, as suggested by previous enzymatic 
deglycosylation analyses. 
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Figure 5.4.2: MALDI/TOF-MS spectrum of permethylated N-glycans released from 
immunoprecipitated FLAG-REST protein extracts. 
 
 
5.4.2 GLYCOSYLATION SITE MAPPING 
 
Additional information on REST glycosylation can be obtained by site mapping, since the 
incontrovertible identification of REST aminoacidic residues target of glycosylation can 
be obtained only through mass spectrometry. For this purpose purified protein extracts 
have been analyzed through MS/MS by the Complex Carbohydrate Research Center 
(University of Georgia). In particular, to elucidate N-linked sites a 18O-labeling method 
was used. Samples are digested with protease and the glycopeptides deglycosylated with 
PNGase F in H218O, converting the asparagine into an aspartic acid, are labeled with 18O: 
the glycosylated peptide will show an increase of 3 Da mass compared to the non-
glycosylated peptide. A mixture of peptides is then analyzed by C18 capillary liquid 
chromatography LC-MS: the data acquisition process included a full mass spectrometry 
scan followed by MS/MS fragmentation of the most intense ion selected from the full MS 
spectrum, by an LTQ (Linear Trap Quadrupole) instrument. Data obtained were searched 
against the REST sequence and general protein database (see paragraph 4.7). N-
glycosylation site mapping of REST indicated twelve potential N-glycosylation sites: 
Asn59, Asn83, Asn417, Asn440, Asn482, Asn553, Asn586, Asn914, Asn958, Asn963, 
Gal
GlcNAc
Man
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Asn1000 and Asn1022: the potential N-glycosylation sites of REST are shown in Table 
5.4.1.  
 
Sequon Digestion 
Peptide 
position Peptide sequencea 
Theoretical 
(m/z) 
Observed 
(m/z) z 
Asn59 
- 
- 
- 
- - 
 
Asn83 Trypsin/Glu-C 76-88 (E)LMPVGDNN@FSDSE(E) 1427.5881 - 1 
Asn417 
- 
- - - - 
 
Asn440 Trypsin 434-445 (R)EADLPDN@ITNEK(T) 1361.6317 - 1 
 
 
  681.3195 - 2 
Asn482 Trypsin 478-493 (K)KPSNN@VSVIQVTTRTR(K) 1802.9969 1802.9471 1 
 
 
  902.0021 901.9772 2 
Asn553 Trypsin 553-564 (K)N@NSQEVPKGDSK(V) 1305.6167 1305.6347 1 
 
 
  653.3120 653.3201 2 
Asn586 
- 
- - - - 
 
Asn914 Trypsin/Glu-C 905-915 (E)SLPGLAANIN@E(S) 1101.5672 - 1 
Asn958 Trypsin/Glu-C 958-967 (E)N@LTGINSTVE(E) 1050.5199 - 1 
Asn958, 963 Trypsin/Glu-C 958-967 (E)N@LTGIN@STVE(E) 1053.5082 - 1 
Asn1000 Trypsin/Glu-C 
988-
1001 (K)TALASPPATMAAN@E(S) 1347.6347 - 1 
Asn1022 Trypsin/Glu-C 
1016-
1025  (E)GSDLSDN@MSE(G)  1057.3876  - 1 
 
Table 5.4.1: Potential N-linked glycosylation site mapping of Trypsin digests from REST sample. 
(@  indicates the site of N-glycosylation). 
 
Asn482 and Asn553 were shown to be glycosylated by LC-MS/MS (Figure 5.4.3) and 
database searching using the TurboSequest algorithm (Figure 5.4.4): the sample showed 
doubly charged ions at m/z 901.98 (Figure 5.4.3 A) and at m/z 653.32 (Figure 5.4.3 B), 
which correspond to the 18O labeled deglycosylated peptide containing Asn482 and 
Asn553. MS/MS spectra showing the localization of N-linked glycosylation sites for 
Asn482 with cross-correlation score (X corr = 0.70) and Asn553 (X corr = 0.45) on 
REST are presented in Figure 5.4.4; however, whether site Asn482 and Asn553 are truly 
glycosylated remains questionable, due to the fact that the X corr values of the 18O-site 
mapping are under confident values (for a double charges ion peptide, its Sequest cross-
correlation score must be >2 to be confident [Link et al., 1999]).   
The other potential N-linked glycosylation sites of REST cannot be detected by 18O-site 
mapping, suggesting that the protein could be highly glycosylated, which affected C18 
binding ability and the elution time. 
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Figure 5.4.3: Full Fourier transform mass spectrometry (FTMS) spectra of 18O labeled 
deglycosylated peptides of REST. A) doubly charged deglycosylated peptide ion 
(K)KPSNN@VSVIQVTTRTR(K), containing Asn482 , m/z 901.98 ; B) doubly charged 
deglycosylated peptide ion (K)N@NSQEVPKGDSK(V), containing Asn553 , m/z 653.32. 
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Figure 5.4.4: MS/MS spectra showing localization of glycosylation site on REST by Trypsin and 
PNGase F digestion and 18O labeling of Asn residues carrying glycans. A) peptide containing 
Asn482 at m/z 901.98 [(K)KPSNN@VSVIQVTTRTR(K)]; B)  peptide containing containing 
Asn553 at m/z 653.32 [(K)N@NSQEVPKGDSK(V)]. 
 
Thus, glycopeptides obtained after tryptic digestion have been O-deglycosyalted through 
β-elimination in mild conditions followed by Michael addition (BEMAD), in order to 
remove O-linked glycans, and then analyzed by mass spectrometry using a direct infusion 
technique: even after O-linked deglycosylation, REST glycopeptides were not confidently 
detected by LC-MS/MS, most likely because of un-appropriated sizes and solubility of 
their sequences.  
 
 
5.5 SITE-DIRECTED MUTAGENESIS 
 
To continue the characterization of the glucidic component present in the REST protein 
and its impact in the transcription factor’s function, I applied a site-directed mutagenesis 
 
B 
 
A 
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strategy mutating several aminoacids predicted to be target of glycosylation. The aim was 
to verify variations in REST molecular weight, DNA binding activity or repressor 
function  consequently to the removal of a single glycan chain or of all of them. 
 
 
5.5.1 PREDICTION OF GLYCOSYLATION SITES IN REST 
 
In order to investigate possible glycosylation sites on REST protein, different software 
have been used to submit REST sequence to the prediction aminoacidic residues target of 
both N- and O-linked glycosylation.  
Although O-linked N-acetylgalactosamine is one of the main types of glycosylation in 
mammalian cells, no consensus sequence is known, making prediction methods necessary 
to bridge the gap between the large number of known protein sequences and the small 
number of proteins experimentally investigated with regard to glycosylation status. 
NetOGlyc is a revised non-redundant database of glycoproteins with O-linked 
glycosylation sites, rating 242 glycoprotein entries: the server produces neural network 
predictions of mucin type N-acetylagalactosamine (GalNAc) O-glycosylation sites in 
mammalian proteins. Examination of REST sequence with NetOGlyc found out several 
putative O-glycosylation sites: sequence analysis generated a graph in which the 
probability of each residue to be glycosylated was represented and compared to a set 
threshold  (Figure 5.5.1 A). NetOGlyc analysis on REST protein sequence predicted  one 
putative site modified with O-GalNAc: threonine 618.  
Like ‘mucin type’ O-glycosylation, also O-linked-β-N-acetylglucosamine (O-GlcNAc) 
does not display a definite consensus sequence: however the motif is marked by specific 
characteristics that help defining region surrounding the glycosylation site. Moving from 
these considerations neural networks on 40 experimentally determined O-GlcNAc 
acceptor sites have been created, generating the YinOYang server, a good predictor for 
O-GlcNAc attachment sites in eukaryotic protein sequences: using this server eleven O-
GlcNAc sites have been predicted in REST protein (Figure 5.5.1 B). 
Furthermore prediction of N-glycosylation target sites has been performed. The 
consensus sequence, Asn-Xaa-Ser/Thr, is known to be a prerequisite for the 
modification; however not all of these sequons are modified and it is thus not 
discriminatory between glycosylated and non-glycosylated asparagines. The NetNGlyc 
prediction server predicts N-glycosylation sites in human proteins, using artificial neural 
networks that examine the sequence context of Asn-Xaa-Ser/Thr sequons, and allows the 
discrimination between acceptor and non-acceptor sequons: submitting REST protein 
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sequence to NetNGlyc, twelve Asn have been obtained as output, with seven of them 
being highly probable N-glycosylated (Figure 5.5.1 C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.1: Prediction of putative glycosylation sites on REST sequence. A) ‘mucin-type’ O-
glycosylation; B) O-linked-β-N-acetylglucosamine (O-GlcNAc); C) N-linked glycosylation. 
 
 
Table 5.5.1 summarizes the prediction results obtained so far, regarding both O- and N-
linked glycosylation. 
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GLYCOSYLATION POSITION RESIDUE PROBABILITY MUTATION 
O-GalNAc 618 Thr  T618A 
3 Thr +  
312 Ser +  
313 Ser +  
484 Ser +  
588 Ser +  
589 Ser +  
618 Thr +  
857 Thr +  
971 Ser ++ S971A 
986 Ser +  
O-β-GlcNAc 
996 Thr +  
59 Asn +++ N59Q 
83 Asn ++ N83Q 
417 Asn ++ N417Q 
440 Asn ++ N440Q 
482 Asn + N482Q 
553 Asn -  
586 Asn -  
914 Asn -  
958 Asn ++ N958Q 
963 Asn -  
1000 Asn + N1000Q 
N-glycosyaltion 
1022 Asn -  
 
Table 5.5.1: Prediction of aminoacids target of glycosylation. The residues highlighted by 
coloured rectangles have been subjected to site-directed mutagenesis for subsequent analysis. 
 
 
5.5.2 MUTAGENESIS OF PREDICTED GLYCOSYLATED 
AMINOACIDS  
 
Aminoacids predicted to be glycosylated with the highest probabilities were subjected to 
site-directed mutagenesis, in order to convert them to targets that are not recognized by 
glycosyltransferases anymore. Site-directed mutagenesis allowed the characterization of the 
complex structure-activity relationship. In fact, inserting a point mutation in REST coding 
sequence it is possible to block the addition of oligosaccharides to the previously 
predicted aminoacids. The QuikChange II XL Site-Directed Mutagenesis kit (Agilent 
Technologies) has been used, coupled with specific primers which contain the desired 
mutation themselves (see paragraph 4.9 and table 4.1 for primers). 
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In particular codons corresponding to serine (TCA) and threonine (ACA) residues, target 
of O-linked glycosylation, have been converted to alanine (GCA), while codons 
corresponding to asparagine (AAT), predicted to be target of N-glycosylation, have been 
converted to glutamine (CAA): we made these substitutions because although they 
prevent the addition of glycan chains in correspondence to the modified aminoacid, they 
allow the maintenance of physico-chemical properties of the protein. Regarding O-
glycosylation, we generated a REST mutant form for ‘mucin-type’ glycosylation, where 
threonine 618 was converted to alanine (T618A REST). In addition, also some of the O-
β-GlcNAc target residues have been subjected to site-directed mutagenesis, generating 
S128A, T144A and S971A mutants. 
Moreover, all of the asparagines predicted to be target of N-glycosylation (Table 5.5.1) 
have been converted to glutamine, singularly or sequentially, thus obtaining mutant forms 
of REST on multiple residues. 
 
 
 
 
 
 
Figure 5.5.2: Schematic representation of potential N-glycosylation sites predicted in REST 
sequence. 
 
REST single mutants have been obtained using as template REST wild-type, encoded by 
the plasmid pCMV-Tag2B+REST: the resulting mutant forms were S128A, T144A, 
T618A, S971A, N59Q, N83Q, N417Q, N440Q, N482, N958Q, N1000Q.  
Concerning N-linked glycosylation, starting from the single mutant N59Q multiple 
mutants have been obtained, by adding first the N83Q mutation and, thus, obtaining the 
double mutant (2N); then the double mutant was used as template for the mutagenesis of 
the asparagine 417, giving the 3N mutant, and so on until all the seven asparagines 
highlighted in Figure 5.5.2 were mutated to glutamine, thus obtaining the 7N mutant. In 
addition we generated a mutant called N+C, where asparagines 59, 83 and 1000 were 
mutated to glutamine, in order to prevent glycosylation in amino- and carboxy-terminal 
domains of REST, known to be involved in the interaction with the co-represors (see 
paragraph 1.2 and Figure 1.3). 
Figure 5.5.3 shows the schematic representation of the genetic map of the plasmid 
bearing REST coding sequence, where the mutated N-glycosylation sites have been 
N440 N482 N958 N1000N417N59
N83
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reported in purple and the restriction enzymes used for subsequent analysis of the 
mutants in black.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.3: Genetic map of the pCMV-Tag2B+REST plasmid, showing the mutated 
sparagines target of N-glycosylation. 
 
Once completed the mutagenesis procedure, the novel plasmids obtained, each encoding 
for a different mutant form of REST, were analyzed to confirm the presence of the 
desired mutation and the absence of any unwanted modification in the coding sequence. 
This was ascertained through restriction analysis and electrophoresis separation of the 
DNA fragments and, then, by sequencing the mutated plasmids to finally verify that the 
right mutation was obtained. 
An example of restriction analysis and agarose gel electrophoresis of the mutant N1000Q 
is reported in Figure 5.5.4 A. I employed the enzyme XhoI to linearize the plasmid and 
obtain a linear fragment of 8374 base pairs (bp), the enzyme SacI to get two fragments of 
7810 and 564 bp, and the enzyme SspI which cuts the plasmid into four fragments of 
4588, 2512, 721 and 553 bp. Mutants containing the N440Q convertion, both single and 
multiple, showed a different pattern of restriction fragments due to the fact that one of 
the four restriction sites recognized by the enzyme SspI (5’ -AATATT- 3’) is lost during 
mutagenesis as it corresponds to the codon encoding asparagine 440. Therefore, as 
consequence of this mutation, only three fragments were obtained following restriction 
analysis, of 7100, 721 and 553 bp, the heavier of which results from the addition of the 
two fragments of 4588 and 2512 bp (Figure 5.5.4 B).  
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Figure 5.5.4: agarose gel electrophoresis of two representative mutant-REST plasmids, after 
restriction analysis with the enzymes XhoI, SacI and SspI. Red arrows highlight the difference of 
restriction fragments obtained after SacI treatment, in presence (B) or absence (A) of the N440Q 
mutation. 
 
Finally, all the mutant plasmids so far obtained were subjected to sequencing analysis 
(BMR Genomics, Padua, Italy). In Figure 5.5.5 is reported the sequence analysis of 
N1000Q mutant as an example of the strategy we used. First we analyzed the 
chromatograms, to check peak size and the absence of any contaminating sequence; then 
we aligned the mutant sequence thus obtained to REST wild-type sequence, to confirm 
the presence of the desired mutation and the absence of any other unwanted modification 
of the plasmid DNA. 
 
 
 
 
 
 
 
 
 
Figure 5.5.5: Sequence analysis of the mutated nucleotidic portion of REST after site-directed 
mutagenesis of N1000Q residue. A) Chromatogram obtained as a result of the sequencing 
analysis; B) Alignment of mutant and wild-type sequences. The mutant codon is highlighted in 
red. 
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5.6 FUNCTIONAL ANALYSIS OF THE MUTANT FORMS OF REST  
 
Once the mutant REST coding sequences have been obtained and validated, the plasmids 
were transfected to transiently express mutant REST proteins in two different cell lines: 
PC-12 and HEK-293 cells, the first because among the neuronal cells is almost absent the 
expression of native REST. This property is particularly useful for the evaluation of 
mutant protein behaviour and activity. The second cell line it is a human embryonic 
model of epithelial origin that differs from the rat neuron-like model of PC-12 cells. 
 
 
5.6.1 WESTERN BLOTTING ANALYSIS OF MUTANT REST 
 
To verify the correct expression of recombinant mutant REST forms, nuclear protein 
extracts of transiently transfected cells were analyzed by western blotting, using both the 
anti-REST (Figure 5.6.1) and anti-FLAG (Figure 5.6.2) antibodies. By comparing band 
migration of wild-type and mutant REST samples in SDS-PAGE I have been able to 
observe that the removal of glycan chains, both N- and O-linked, did not alter REST 
apparent molecular weight.  
Looking at the single mutants we first hypothesized that a small variation of apparent 
molecular weight, such the one consequent to the removal of a single N-linked 
oligosaccharide, could be hardly appreciated by western blotting; we expected multiple 
mutants, such as 7N REST, to show a significant reduction of apparent molecular weight 
of about 15 kDa, as suggested by mass spectrometry data (see paragraph 5.4.1 and Figure 
5.4.2). None of the REST mutant forms that we generated and analyzed showed 
alterations of the apparent molecular weight after site-directed mutagenesis and glycan 
chains removal. 
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Figure 5.6.1: Western blotting analysis of nuclear protein extracts of the wild-type and mutant 
FLAG-REST protein expressed in PC-12 cells, using the anti-REST antibody. A) single mutant 
forms of REST; B) 7N and N+C mutant REST. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6.2: Western blotting analysis of nuclear protein extracts of the wild-type and mutant 
FLAG-REST protein expressed in PC-12 cells, using the anti-FLAG antibody. A) single mutant 
forms of REST; B) 7N and N+C mutant REST. 
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5.6.2 EVALUATION OF MUTANT REST DNA BINDING  
 
REST mutant forms have been evaluated for their ability to recognize and bind the RE-1 
consensus sequence in comparison to the wild-type protein: the aim was that of testing 
the possible role of glycan chains in modulating binding affinity of REST to DNA, 
mimicking this interaction in vitro through Electrophoretic Mobility Shifting Assay 
(EMSA), by using a specific fragment of the human µ-opioid receptor gene promoter, 
already known to be regulated by REST activity [Bedini et al., Neurochemistry 
International 2009]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6.3: EMSA analysis of nuclear protein extracts of the wild-type and mutant FLAG-
REST protein expressed in PC-12 cells. A) A representative experiment comparingf binding 
capability of single mutant REST forms and wt REST; B) A representative experiment showing 
the specificity of the complex, confirmed by the unlabeled and supershift samples; C) Densitometric 
analysis of three different experiments. 
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Nuclear protein extracts of N-linked single mutants, double mutant N59+N83 and 7N 
mutant transiently transfected in PC-12 cells have been evaluated, in parallel with nuclear 
protein extracts of native PC-12 cells (PC-12 sample), showing low levels of endogenous 
REST, and of cells transfected with the wild-type protein (wt REST) (Figure 5.6.3 A).  
In addition, to verify that REST binding to the oligonucleotide is selective and to 
discriminate the specific band corresponding to this interaction, EMSA was run in 
absence of any protein extract (oligo), in presence of an unlabeled oligonucleotide, 
functioning as a competitor for protein binding to biotinilated oligonucleotide (unlabeled), 
and in presence of a specific anti-REST antibody (Figure 5.6.3 B): in this latter case 
(supershift), the antibody causes a visible reduction in band intensity of about 30%, thus 
confirming the specificity of the interaction (see the blue arrow). Moreover, as highlighted 
in the red rectangle, the incubation of the complex with an excess of unlabeled 
competitor reduces REST band intensity in a way that is proportional to competitor 
concentration, of about 25% and 37% respectively. 
In Figure 5.6.3 A it is reported that all mutant REST bands migrate at the same height as 
wt REST, indicating that no variations in REST:RE-1 complex occurred; in addition, 
densitometric analysis of each band intensity revealed that removal of single glycan chains 
from the transcription factor did not alter its affinity to DNA (Figure 5.6.3 C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6.4: EMSA analysis of nuclear protein extracts of the wild-type, N+C and 7N mutant 
FLAG-REST protein expressed in PC-12 cells. The red arrow indicates the band corresponding 
to REST:RE-1 complex. 
 
Subsequently the ability of multiple mutant REST to bind DNA consensus sequence was 
assayed: again, 7N and N+C REST mutant forms did not show any variation in migration 
nor in band intensity, if compared to wt REST (Figure 5.6.4). I then decided to compare 
the interaction between DNA and mutant or wild-type REST forms expressed in HEK-
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293 cells, to evaluate expression and binding affinity of the protein in a different cellular 
context (Figure 5.6.5 A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6.5: EMSA analysis of nuclear protein extracts of the wild-type and mutant FLAG-
REST protein expressed in HEK-293 cells. A) Representative experiment comparing binding 
capability between mutant REST forms and wt REST; B) Representative experiment reporting 
the specificity of the complex has been confirmed by the unlabeled and supershift samples; C) 
Densitometric analysis of three different experiments. 
 
To verify the specificity of REST binding to the oligonucleotide EMSA experiments were 
done in absence of any protein extract (oligo), in presence of an unlabeled oligonucleotide 
(unlabeled), and in presence of a specific anti-REST and anti-FLAG antibody (Figure 5.6.5 
B): the incubation of the complex with an excess of unlabeled competitor reduces REST 
band intensity of about 20% and 30%, as the concentration of the competitor increases. 
The presence of the antibody causes a visible reduction in band intensity, of about 20% 
with the anti-REST antibody and 30% with the anti-FLAG antibody, although any 
supershift was observed.  
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The removal of single N-linked glycan chains from asparagine 59 and 83 of REST 
expressed in HEK-293 cells caused a slight but not statistically significant reduction in the 
affinity of protein:DNA complex formation, as shown by the densitometric analysis of 
band intensities (Figure 5.6.5 C); in addition all mutant REST bands migrate at the same 
height as wt REST, indicating that any variation in REST:RE-1 complex occurred. 
However the double mutant N59+N83 (2N sample) showed a reduction in DNA binding 
of about 25%, as shown by the blue arrow in Figure 5.6.5 C.  
 
 
5.6.3 TRANSCRIPTIONAL ACTIVITY OF MUTANT REST 
 
Previous data indicate that neither apparent molecular weight nor DNA recognition and 
binding are affected by N-glycan chains removal after site-directed mutagenesis. 
However, I decided to test repressor activity of several mutant REST forms in 
comparison to the wild-type protein: this could be possible through the use of gene 
reporter assays, where the expression of a reporter gene, the firefly luciferase gene in this 
case, is driven by the activity of a fragment of the µ-opioid receptor gene promoter 
(hMOR), already known to be negatively regulated by REST [Bedini et al., 
Neurochemistry International 2009]. 
The assay was set in PC-12 cells, a cellular model chosen because of the minimal 
expression of endogenous REST protein: in such conditions luciferase transcription is 
regulated only by the activity of over-expressed recombinant REST, wild-type or mutant. 
PC-12 cells have been transiently co-transfected with three different expression plasmids: 
the reporter plasmid encodes for firefly luciferase cloned downstream of the human 
hMOR promoter (pGL3+LNpMOR); another plasmid encodes for the wild-type or 
mutant form of recombinant FLAG-REST, whose expression is driven by a strong viral 
promoter (pCMV-Tag2B+REST); the third plasmid has been chosen as a normalization 
control, since it encodes for the beta-galactosidase enzyme put under the control of the 
SV40 constitutive promoter (pSV-βGal).  
The transcriptional activity of each construct is expressed as luciferase activity relative to 
the activity of non-transfected cells (pGL3 empty sample). Transfection efficiencies have 
been normalized to an internal control plasmid pSV-βGal, measuring  β-galactosidase 
activity. 
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Figure 5.6.6: REST-dependent effects on the transcriptional activity of different hMOR 
promoter fragments in neuron-like PC-12 cells. Green bars represent control samples; blue bars 
represent IGF-I treated (10 nM, 24h) samples. Data are presented as mean ± SEM of four 
independent experiments run in triplicate. 
 
As shown in Figure 5.6.6, in cells transfected with the reporter plasmid alone 
(pGL3+LNpMOR sample) the over-expression of luciferase is translated to an increment 
of relative luminescence units (RLU), as indicated by the statistically significant increase of 
the pGL3+LNpMOR green bars over the pGL3 empty sample. 
The addition of wild-type REST-encoding plasmid to the reporter plasmid causes the 
concurrent over-expression of the transcriptional repressor, which can bind RE-1 
consensus sequence on hMOR promoter and thus it decreases luciferase activity. In fact, 
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as can be observed in the figure, luminescence of wt REST samples is reduced if 
compared to pGL3+LNpMOR, returning to RLU levels of the pGL3 empty samples 
(compare wt REST green bars to pGL3+LNpMOR and pGL3 empty ones). These data 
confirm the efficacy of the system and allowed to proceed with the analysis using mutant 
REST forms. 
The co-transfection of luciferase reporter plasmid and mutant REST, instead of wild-type 
REST, showed RLU levels similar to cells transfected with  pGL3+LNpMOR alone (see 
N59, N83, 2N or 7N green bars): these results indicate that luminescence activity in 
presence of mutant REST is reverted to the one observed in samples where REST is 
absent, thus suggesting that removal of N-linked glycan chains causes loss of the 
transcriptional repressor function.  
Moreover, I checked the effect of Insulin-like Growth Factor I (IGF-I) treatment on co-
transfected PC-12 cells. This is a trophic factor that activates STAT3 transcription factor 
and thus stimulates hMOR transcriptional activity. IGF-I treatment (10 nM, 24 hours) 
increases luciferase activity and allows an easy detection of any slight variation in 
luciferase transcription and activity, thus permitting data analysis even in presence of a 
transcriptional repressor as REST. In cells co-transfected with the reporter plasmid in 
conjunction with different mutant REST forms and treated with IGF-I, RLU levels vary 
according to the mutation analyzed (see N59, N83, 2N or 7N blue bars). Removal of N-
linked glycan chain from asparagine 59 (Figure 5.6.6.A), for instance, causes a complete 
loss of repressor activity in control samples, but IGF-I treated samples maintain a slight 
residual repressor activity: this could be due to the fact that asparagine N59 is not crucial 
for REST-mediated transcriptional repression and any residual activity of the protein 
could be enforced by the activation of other transcription factors, mediated by IGF 
treatment, that could balance REST disfunction. 
On the contrary other mutants analyzed, N83, 2N and 7N REST, show a complete loss 
of function even after IGF-I treatment and beave exactly as the control samples (Figure 
5.6.6 B, C and D), suggesting that asparagine 83, which is mutated in each of the forms, 
may play a more critical role in determining REST transcriptional repressor function. 
REST mutant forms analyzed so far have been chosen because of their position in the 
protein sequence, since asparagines 59 and 83 are known to be involved in the interaction 
with the co-repressor mSin3A, whose activity is crucial for the repressor activity (see 
paragrapch 1.2). These experiments confirm that N-glycosylation of the transcription 
factor REST plays a fundamental role in determining co-repressors recruitment. 
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6.  DISCUSSION  
 
Gene expression is regulated both by positively acting cell-type-specific transcription 
factors and negative-acting silencers, that can participate in preventing the expression of 
neuronal genes in non-neuronal cell types or in inappropriate neuronal subtypes.  
REST [Chong et al., 1995], also known as NRSF [Schoenherr and Andreson 1995], is a 
zinc-finger transcription factor that blocks transcription of its target genes by binding to a 
21-bp DNA consensus sequence (the repressor element 1, RE-1, or neuron-restrictive 
silencer element, NRSE) present in the target genes’ regulatory region. REST has been 
implicated in several processes such as maintenance of embryonic stem cell pluripotency, 
self-renewal and regulation of mitotic fidelity in non-neuronal cells.  
REST gene encodes for a 116-kDa protein that contains a DNA-binding domain 
composed of eight zinc-fingers, an N-terminal repressor domain and one zinc finger at 
the C-terminal repressor domain [Ballas and Mandel, 2005]: by acting as an evolving 
molecular platform to which diverse factors may be recruited, REST promotes dynamic 
modifications of DNA, histones, nucleosomes and higher-order chromatin codes and 
helps maintaining genomic stability.  
Although REST molecular weight, calculated on aminoacid sequence, is about 116 kDa it 
was found to migrate on SDS-PAGE as a protein of different molecular weights (see 
Table 1.1), consistent with the possible presence of post-translational modifications in the 
protein backbone: it has been recently observed the presence of O-glycan chains in  
REST, suggesting the importance of glycosylation in modulating transcriptional activity 
[Lee et al., 2000]. The most common way that diversity is generated in proteins is 
alteration of the composition of the constituent amino acids; however additional diversity 
is generated by covalent modification of amino acids by post-translational modifications 
(PTMs) [Vosseller et al., 2001]. Among post-translational modifications the most 
common is the complex process of glycosylation, that is the covalent attachment of one 
or more carbohydrates that occurs during or after the process of protein synthesis: it has 
been estimated that more than one half of all proteins are glycosylated [Apweiler et al., 
1999]. Glycosylation may affect many protein activities, can facilitate folding kinetics and 
affect the biophysical properties of proteins. The fact that N-glycosylation starts during 
protein synthesis indicates that it may assist in obtaining the correct fold [Roth et al., 
2010]. On the contrary O-linked glycans, which often have lower mass than N-linked 
structures and higher heterogeneity, have been found to function in protein structure and 
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stability, immunity, receptor-mediated signaling, protein interactions, expression and 
processing. Moreover the discovery of O-linked-β-N-acetylglucosamine (O-GlcNAc) 
disproved the long-held dogma that protein glycosylation is restricted to the luminal 
compartments of the secretory machinery and to the cell surface: several transcription 
factors are O-GlcNAcylated, with the modification being involved in nuclear transport, 
DNA binding and assembly into multimeric complexes [Torres and Hart, 1984]. 
Alterations in any step of the N- and O-glycosylation process can be involved in the 
aetiology of many human disorders, such as congenital diseases, diabetes, neuronal 
degeneration and cancer [Wopereis et al., 2006]. REST, as well, has been found to be 
involved in the establishment of the same diseases: particularly it showed a double role in 
the pathogenesis of cancer, since it can behave both as an oncogene and an 
oncosuppressor [Coulson JM, 2005].  
Moving from these observations, in this thesis I have demonstrated the presence of N-
linked glycan chains in the aminoacidic backbone of REST and related this post-
translational modification to the repressor transcriptional activity. 
First of all, I have observed that REST protein migrates on SDS-PAGE with a specific 
pattern of bands, differing among various cell lines and between the nuclear and the 
cytosolic form of the protein. Then, I moved my attention to oligosaccharide 
composition of the glycan chains present in REST: for this purpose I applied a strategy of 
enzymatic deglycosylation, using different combinations of enzymes capable of 
specifically remove the glucidic residues from the endogenous protein. I evaluated the 
presence of N-linked oligosaccharides by the action of PNGase F, which removes intact 
N-linked oligosaccharides from glycoprotein, and Endoglycosidases F1, F2 and F3, that 
cleave the native protein between the two N-acetylglucosamines. Furhtermore, I tested 
the activity of enzymes involved in the removal of O-linked glycans, such as Endo-α-N-
acetylgalactosaminidase, α2-3,6,8,9-neuraminidase, β1,4-galactosidase and β-N-acetylglucosaminidase. 
Treatment of endogenous REST with PNGase F did not cause any alteration in the 
migration of the protein in the SDS-PAGE, while Endoglycosidase F1 caused the 
appearance of an additional band of apparent molecular weight of about 180 kDa; 
similarly the combination of all the enzymes necessary for O-glycosylation removal (Endo-
α− N-acetylgalactosaminidase + Galactosidase + Neuraminidase + β-N-acetylglucosaminidase), 
caused the appearance of one additional band, whose apparent molecular weight is about 
180 kDa. Similar results have been observed for the recombinant FLAG-REST protein 
expressed in HEK-293 cells, with the appearance of the 180 kDa band subsequently to 
the treatment with the Endo-α + Galactosidase combination or with Endoglycosidase F1, and 
the increment of intensity of the band of 120 kDa, corresponding to the non-glycosylated 
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form of REST. Starting from these observations, I hypothesized the presence of both O-
linked and N-linked glycan chains: the latter could be buried in the protein core structure 
and thus unaccessible for the enzyme. 
To further confirm the hypothesis that REST is modified by the addition of complex 
glycan chains in the protein backbone, I evaluated apparent molecular weight of synthetic 
REST protein produced in a prokaryotic and an eukaryotic cell-free system: in fact only 
eukaryotic extracts are able to synthesize REST protein with the proper folding and post-
translational modifications, while E.coli produced-REST migrated in SDS-PAGE with an 
apparent molecular weight of about 120 kDa, comparable to the non-glycosylated form of 
endogenous REST. 
To finally depict the glycan chains in terms of oligosaccharide composition and linkage 
analysis, I have subjected recombinant REST protein extracts, obtained from HEK-293 
cells stably expressed with the FLAG-REST plasmid construct, to mass spectrometry 
analysis: for this purpose the protein had to by affinity-purified using an agarose resin 
conjugated with anti-FLAG antibody, in order to enrich the fully glycosylated form. 
Purified protein extracts have been analyzed through MALDI/TOF mass spectrometry. 
REST has been shown to have a very complex mixture of glycans; however, there are 
some dominant glycans having higher peak intensities, which confirmed the presence of 
N-linked glycan chains composed of N-acetylgalactosamine, galactose and mannose, as 
suggested by previous enzymatic deglycosylation analyses.  
Subsequently in order to fulfil glycosylation site mapping, purified protein extracts have 
been analyzed through MS/MS. In particular, to elucidate N-linked sites 18O-labeling 
method has been used. Twelve potential N-glycosylation sites have been identified: 
Asn59, Asn83, Asn417, Asn440, Asn482, Asn553, Asn586, Asn914, Asn958, Asn963, 
Asn1000 and Asn1022, and Asn482 and Asn553 of REST were shown to be glycosylated 
by LC-MS/MS. However, whether sites Asn482 and Asn553 are truly glycosylated 
remains questionable, due to the fact that the X corr values of the 18O-site mapping are 
under confident values; the other potential N-linked glycosylation sites of REST cannot 
be detected by 18O-site mapping, suggesting that the protein might be highly glycosylated. 
Thus glycopeptides obtained after tryptic digestion have been O-deglycosyalted through 
β-elimination in mild conditions followed by Michael addition, in order to remove O-
linked glycans, and then analyzed by mass spectrometry: even after O-linked 
deglycosylation, REST glycopeptides were not confidently detected by LC-MS/MS, most 
likely because of unappropriated sizes and solubility of their sequences.  
Therefore, using post-translational prediction software I have identified the most 
probable REST residues target of both N- and O-linked glycosylation and mutated them 
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through site-directed mutagenesis. Only one residue was predicted to be modified with 
O-GalNAc in REST protein sequence, which is Thr618; on the contrary, eleven O-
GlcNAc sites have been predicted in REST. Finally submitting REST protein sequence to 
the N-glycosylation prediction server, twelve Asn have been obtained as output, with 
seven of them being highly probable N-glycosylated (Asn59, Asn83, Asn417, Asn440, 
Asn482, Asn958 and Asn1000). All of these residues, in addition to Thr618 and Ser971, 
have been subjected to site-directed mutagenesis, singularly or sequentially, in order to 
convert these residues to aminoacids that are not recognized by glycosyltransferases. Site-
directed mutagenesis allows the characterization of the complex structure-activity 
relationship: inserting a point mutation in REST coding sequence it is possible to block 
the addition of oligosaccharides to target aminoacids, maintaining the protein physico-
chemical properties. The mutant plasmids obtained, each encoding for a different mutant 
form of REST, have been analyzed to confirm the presence of the desired mutation and 
the absence of any unwanted modification of the coding sequence, through restriction 
analysis and sequencing the mutated plasmids to finally verify that the right mutation was 
obtained.  
To verify any variation of REST activity associated to glycan chains removal, REST 
mutant forms have been expressed in different cell lines, of embryonic and neuronal 
origin: first we analyzed variations in the protein molecular weight and observed that any 
of the REST mutant forms that were generated, showed alterations of the apparent 
molecular weight, probably because of the presence of additional glycosylation residues 
not predicted and thus not considered in the mutagenesis procedure. 
Furthermore, to identify the role of glycan chains in modulating binding affinity of REST 
to DNA, I evaluated the ability of different REST forms to bind the RE-1 consensus 
sequence, in presence or absence of glycosylation: any variation in REST:RE-1 complex 
nor any statistically significant variation in band intensity occurred, except that the double 
mutant N59+N83 expressed in HEK-293 cells showed a reduction in DNA binding of 
about 25%. 
Finally, I investigated the role of glycan chains in the modulation of the repressor 
transcriptional activity through gene reporter assays, testing the expression of the firefly 
luciferase driven by the activity of a fragment of the µ-opioid receptor gene promoter 
(hMOR), already known to be regulated by REST [Bedini et al., Neurochemistry 
International 2010]. The assay was set in PC-12 cells, where the expression of endogenous 
REST is barely detectable: in such conditions luciferase transcription is regulated only by 
the activity of over-expressed recombinant REST, wild-type or mutant. 
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The removal of N-linked glycan chains causes loss of transcriptional repressor function; 
in cells co-transfected with the reporter plasmid in conjunction with different mutant 
forms and treated with IGF-I, luciferase levels vary according to the mutation analyzed. 
Removal of N-linked glycan chain from asparagine 59 showed a slight residual repressor 
activity in presence of IGF-I: this could be possibly due to the fact that asparagine N59 is 
not crucial for REST-mediated transcriptional repression and any residual activity of the 
protein could be enforced by the activation of other transcription factors, mediated by 
IGF treatment, that can compensate for REST disfunction. On the contrary the other 
mutants analyzed, each containing N83 mutation, showed the complete loss of function 
even after IGF-I treatment, suggesting that asparagine 83 may play a more critical role in 
determining REST transcriptional repressor function. 
My thesis has ascertained, for the first time, the presence of complex glycan chians in the 
transcription factor REST. I have depicted their composition, started defining their 
position on the protein backbone and identified their possible role in the transcription 
factor functioning. 
REST mutant forms analyzed so far have been chosen because of their position in the 
protein sequence, since asparagines 59 and 83 are known to be involved in the interaction 
with the co-repressor mSin3A, whose activity is crucial for the repressor activity. My 
experiments confirmed that N-glycosylation of the transcription factor REST plays a 
fundamental role in determining co-repressors recruitment (Figure 6.1). 
This study demonstrated the presence of a complex pattern of glycosylation on an nuclear 
protein, such as a transcription factor, event that seemed to be very unlikely: complex 
glycosylation is a well known and very common process for proteins that reside in the 
luminal compartments of the secretory machinery and to the cell surface; however the 
possible role for the presence of heavy and complex oligosaccharides in a nuclear protein 
remains to be elucidated. 
Several transcription factors have been shown to be modified by the addition of O-
linked-β-N-acetylglucosamine (O-GlcNAc), with the modification being involved in 
nuclear transport, DNA binding and co-repressors recruitment [Torres and Hart, 1984]. 
One example is Sp1, a ubiquitously expressed transcription factor particularly important 
for the regulation of TATA-less genes that encode housekeeping proteins, such as growth 
factors and receptors: it has been shown that Sp1 is multiply O-GlcNAcylated and its 
activity is regulated by glucose and glucosamine availability, with Sp1 being rapid 
proteolytically degraded when hypoglycosylated. Thus, O-GlcNAc modification of Sp1 
may play a role as a nutritional checkpoint related to growth factor gene transcription: in 
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the absence of adequate nutrition, Sp1 becomes hypoglycosylated and is rapidly degraded, 
resulting in reduced general transcription [Han and Kudlow, 1997].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Schematic representation of potential role of N-glycan chains present in asparagines 
59 and 83 of REST sequence. A) transcriptional repressive state maintained by REST binding on 
RE-1 consensus sequence and by recruitment of the mSin3 and CoREST co-repressor 
complexes; B) loss of REST-mediated transcriptional repression after N59 and N83 N-glycan 
chains removal, due to the failed recruitment of mSin3 co-repressor complex. 
 
CREB (cyclic AMP-responsive element binding protein), a transcription factor essential 
for long-term memory, is covalently modified by O-GlcNAc: it ha been demonstrated 
that the presence of O-GlcNAc impairs the ability of CREB to associate with TAFII130 
and to activate transcription. These findings have important implications for the role of 
O-GlcNAc glycosylation in gene regulation, and provide the first link between O-
GlcNAc and information storage processes in the brain [Lamarre-Vincent and Hsieh-
Wilson, 2002]. 
On the contrary, the involvement of N-linked glycosylation in eukaryotic transcription 
factors’ activity is scarcely known and only few transcription factors have been identified 
to be N-glycosylated so far. The Activating Transcription Factor 6 (ATF6), a member of 
the ATF/CREB family transcription factors, has two isoforms of 90 kDa (ATF6α) and 
110 kDa (ATF6β): the latter contains five evolutionarily conserved N-linked glycosylation 
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sites and is a key transcriptional repressor of ATF6α, which regulates the strength and 
duration of ATF6-dependent ER stress response (ERSR) gene induction. It has been 
recently shown that unglycosylated ATF6β cannot be proteolytically cleaved to 
p60ATF6β, that actually inhibits ATF6α-mediated ERSR gene activation: thus, 
unglycosylated ATF6β may directly facilitate the expression of ERSR genes by losing its 
repressor function to ATF6α. One possible explanation is that different states of 
ATF6β N-glycosylation may affect protein topology or protein-protein interactions, 
required for its processing; in addition, loss of N-linked glycan chains from ATF6β could 
prevent its normal localization and such mutant could not be available for normal 
proteolysis [Guan et al., 2009]. 
To fully understand the role of glycosylation in REST repressor activity and correctly 
define the molecular mechanisms underlying this event, it will be necessary to identify the 
exact position of glycan chains in REST aminoacidic sequence by mass-spectrometry 
analysis. Moreover, to further confirm my results, the interaction among REST and co-
repressors should be further investigated, possibly through co-immunoprecipitation 
assays, in order to correlate glycan chains presence to transcriptional repressor activity. 
In conclusion, the present study aims to contribute to a more accurate comprehension of 
the processes responsible for REST activity modulation, which is important for a detailed 
knowledge of important events like neurogenesis and oncogenesis; moreover, considering 
the crucial role of glycosylation and transcription factors activity in the aetiology of many 
disease states, any further knowledge could find important and interesting 
pharmacological application. 
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